

# Wetenschappelijk jaaroverzicht 2018



---

# Wetenschappelijk jaaroverzicht 2018

Auteur  
A.M. Kuijpers-Ruurs

# Inhoudsopgave

<b>1</b>	<b>Algemeen</b>	<b>6</b>
1.1	Publicaties met impactfactor	6
1.2	Overige publicaties	10
1.3	Boekbijdragen	10
1.4	Proefschriften en promoties	11
1.5	Posters	11
1.6	Presentaties en abstracts	12
<b>2</b>	<b>Borstkanker</b>	<b>14</b>
2.1	Publicaties met impactfactor	14
2.2	Proefschriften en promoties	17
2.3	Posters	18
2.4	Presentaties en abstracts	19
<b>3</b>	<b>Bot-en wekedelentumoren</b>	<b>22</b>
3.1	Publicaties met impactfactor	22
<b>4</b>	<b>Darmkanker</b>	<b>23</b>
4.1	Publicaties met impactfactor	23
4.2	Overige publicaties	24
4.3	Proefschriften en promoties	24
4.4	Posters	24
4.5	Presentaties en abstracts	24
<b>5</b>	<b>Gynaecologische tumoren</b>	<b>26</b>
5.1	Publicaties met impactfactor	26
5.2	Overige publicaties	28
5.3	Proefschriften en promoties	28
5.4	Posters	29
5.5	Presentaties en abstracts	29
<b>6</b>	<b>Hemato-oncologie</b>	<b>30</b>
6.1	Publicaties met impactfactor	30
6.2	Overige publicaties	31
6.3	Proefschriften en promoties	31
6.4	Posters	31
6.5	Presentaties en abstracts	32
<b>7</b>	<b>Hoofdhalskanker</b>	<b>33</b>
7.1	Publicaties met impactfactor	33
7.2	Posters	34
<b>8</b>	<b>Huidkanker</b>	<b>35</b>
8.1	Publicaties met impactfactor	35
8.2	Presentaties en abstracts	35
<b>9</b>	<b>Longkanker</b>	<b>36</b>
9.1	Publicaties met impactfactor	36
9.2	Overige publicaties	37
9.3	Posters	37
9.4	Presentaties en abstracts	37
<b>10</b>	<b>Neuro-endocriene tumoren</b>	<b>38</b>
10.1	Publicaties met impactfactor	38
<b>11</b>	<b>Neuro-oncologie</b>	<b>39</b>
11.1	Publicaties met impactfactor	39
11.2	Posters	39

---

<b>12</b>	<b>Upper GI &amp; HPB</b>	<b>40</b>
	12.1 Publicaties met impactfactor	40
	12.2 Overige publicaties	42
	12.3 Proefschriften en promoties	42
	12.4 Posters	42
	12.5 Presentaties en abstracts	43
<b>13</b>	<b>Urogenitale kanker</b>	<b>45</b>
	13.1 Publicaties met impactfactor	45
	13.2 Overige publicaties	46
	13.3 Proefschriften en promoties	46
	13.4 Posters	46
	13.5 Presentaties en abstracts	46
<b>B1</b>	<b>Impactfactoren tijdschriften</b>	<b>48</b>

# 1 Algemeen

## 1.1 Publicaties met impactfactor

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, **Visser O**, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group (**Siesling S**). Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018 Jan 30. pii: S0140-6736(17)33326-3. doi: 10.1016/S0140-6736(17)33326-3. [Epub ahead of print]

Impactfactor: 53,254

Bechakra M, Moerdijk F, van Rosmalen J, Koch BC, **van der Rijt CC**, Sillevius Smitt PA, Jongen JL. Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients. *Eur J Cancer*. 2018 Nov 12;105:79-87. doi: 10.1016/j.ejca.2018.09.036. [Epub ahead of print]

Impactfactor: 7,191

Buffart LM, Sweegers MG, May AM, Chinapaw MJ, van Vulpen JK, Newton RU, Galvão DA, Aaronson NK, Stuiver MM, Jacobsen PB, Verdonck-de Leeuw IM, Steindorf K, Irwin ML, Hayes S, Griffith KA, Lucia A, Herrero-Roman F, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, **Velthuis MJ**, Taaffe DR, van Mechelen W, José Kersten M, Nollet F, Wenzel J, Wiskemann J, Brug J, Courneya KS. Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. *J Natl Cancer Inst*. 2018 Oct 9. doi: 10.1093/jnci/djy161. [Epub ahead of print]

Impactfactor: 11,238

Campschroer T, Zhu X, **Vernooij RW**, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones: a Cochrane Systematic Review. *BJU Int*. 2018 Jun 16. doi: 10.1111/bju.14454. [Epub ahead of print]

Impactfactor: 4,688

**de Rooij BH**, **Ezendam NP**, **Mols F**, **Vissers PA**, Thong MS, **Vlooswijk CC**, **Oerlemans S**, Husson O, **Horevoorts NJ**, **van de Poll-Franse LV**. Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: the population-based PROFILES registry. *Qual Life Res*. 2018 Aug 30. doi: 10.1007/s11136-018-1979-0. [Epub ahead of print]

Impactfactor: 2,392

**de Rooij BH**, Park ER, Perez GK, Rabin J, Quain KM, Dizon DS, Post KE, Chinn GM, McDonough AL, Jimenez RB, **van de Poll-Franse LV**, Peppercorn J. Cluster Analysis Demonstrates the Need to Individualize Care for Cancer Survivors. *Oncologist*. 2018 May 8. pii: theoncologist.2017-0558. doi: 10.1634/theoncologist.2017-0558. [Epub ahead of print]

Impactfactor: 5,306

**de Rooij BH**, Thong MS, **van Roij J**, **Bonhof CS**, Husson O, **Ezendam NP**. Optimistic, Realistic, and Pessimistic Illness Perceptions; Quality of Life; and Survival Among 2457 Cancer Survivors: The Population-Based PROFILES Registry. *Cancer*. 2018 Sep 7. doi: 10.1002/cncr.31634. [Epub ahead of print]

Impactfactor: 6,537

Derksen JW, **Beijer S**, Koopman M, Verkooijen HM, **van de Poll-Franse LV**, May AM. Monitoring potentially modifiable lifestyle factors in cancer survivors: A narrative review on currently available methodologies and innovations for large-scale surveillance. *Eur J Cancer*. 2018 Jul 12. pii: S0959-8049(18)30912-2. doi: 10.1016/j.ejca.2018.06.017. [Epub ahead of print]

Impactfactor: 7,191

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *Eur J Cancer*. 2018 Aug 9. pii: S0959-8049(18)30955-9. doi: 10.1016/j.ejca.2018.07.005. [Epub ahead of print] Review.

Impactfactor: 7,191

Florez ID, Veroniki AA, Al Khalifah R, Yepes-Nuñez JJ, Sierra JM, Vernooij RW, Acosta-Reyes J, Granados CM, Pérez-Gaxiola G, Cuello-Garcia C, Zea AM, Zhang Y, Foroutan N, Guyatt GH, Thabane L. Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: A systematic review and network meta-analysis. *PLoS One*. 2018 Dec 5;13(12):e0207701. doi: 10.1371/journal.pone.0207701. eCollection 2018.

Impactfactor: 2,766

Freites-Martinez A, Shapiro J, van den Hurk CJ, Goldfarb S, Jimenez J, Rossi AM, Paus R, Lacouture ME. CME Part 2: Hair disorders in cancer survivors Persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery. *J Am Acad Dermatol*. 2018 Apr 13. pii: S0190-9622(18)30530-9. doi: 10.1016/j.jaad.2018.03.056. [Epub ahead of print] Review.

Impactfactor: 6,898

Geijteman EC, Graaf MV, Witkamp FE, Norden SV, Stricker BH, van der Rijt CC, van der Heide A, van Zuylen L. Interventions in hospitalised patients with cancer: the importance of impending death awareness. *BMJ Support Palliat Care*. 2018 Feb 9. pii: bmjspcare-2017-001466. doi: 10.1136/bmjspcare-2017-001466. [Epub ahead of print]

Impactfactor: 2,385

Hendriks SH, Schrijnders D, van Hateren KJ, Groenier KH, Siesling S, Maas AH, Landman GW, Bilo HJ, Kleefstra N. Association between body mass index and obesity-related cancer risk in men and women with type 2 diabetes in primary care in the Netherlands: a cohort study (ZODIAC-56). *BMJ Open*. 2018 Jan 24;8(1):e018859. doi: 10.1136/bmjopen-2017-018859.

Impactfactor: 2,413

Hollestein LM, Leonardi-Bee J, Lo S, Rosset S, Shomron N. The ABC of reporting statistical analyses in the BJD: Always Be Clear. *Br J Dermatol*. 2018 Jul;179(1):3-5. doi: 10.1111/bjd.16742. No abstract available.

Impactfactor: 6,129

Imbimbo M, Maury JM, Garassino M, Girard N; RARECAREnet Working Group (Visser O). Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. *Eur J Surg Oncol*. 2019 Jan;45(1):75-80. doi: 10.1016/j.ejso.2018.01.078. Epub 2018 Feb 2.

Impactfactor: 3,688

Johnston BC, Alonso-Coello P, Bala MM, Zeraatkar D, Rabassa M, Valli C, Marshall C, El Dib R, Vernooij RW, Vandvik PO, Guyatt GH. Methods for trustworthy nutritional recommendations NutriRECS (Nutritional Recommendations and accessible Evidence summaries Composed of Systematic reviews): a protocol. *BMC Med Res Methodol*. 2018 Dec 5;18(1):162. doi: 10.1186/s12874-018-0621-8.

Impactfactor: 2,524

Kilsdonk MJ, Siesling S, van Dijk BA, Wouters MW, van Harten WH. What drives centralisation in cancer care? *PLoS One*. 2018 Apr 12;13(4):e0195673. doi: 10.1371/journal.pone.0195673. eCollection 2018.

Impactfactor: 2,766

Komen MM, van den Hurk CJ, Nortier JW, van der Ploeg T, Smorenburg CH, van der Hoeven JJ. Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia. *Eur J Oncol Nurs*. 2018 Apr;33:49-55. doi: 10.1016/j.ejon.2018.01.001. Epub 2018 Feb 3.

Impactfactor: 1,812

Kuip EJ, Oldemenger WH, Thijs-Visser MF, de Bruijn P, Oosten AW, Oomen-de Hoop E, Koolen SL, **van der Rijt CC**, Mathijssen RH. Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer. *PLoS One*. 2018 Jun 8;13(6):e0198289. doi: 10.1371/journal.pone.0198289. eCollection 2018.  
Impactfactor: 2,766

Meulepas JM, Ronckers CM, Smets AM, Nievelstein RA, Gradowska P, Lee C, Jahnen A, van Straten M, de Wit MY, Zonnenberg B, Klein WM, Merks JH, **Visser O**, van Leeuwen FE, Hauptmann M. Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands. *J Natl Cancer Inst*. 2018 Jul 18. doi: 10.1093/jnci/djy104. [Epub ahead of print]  
Impactfactor: 11,238

**Mols F**, Husson O, Oudejans M, **Vlooswijk C**, **Horevoorts N**, **van de Poll-Franse LV**. Reference data of the EORTC QLQ-C30 questionnaire: five consecutive annual assessments of approximately 2000 representative Dutch men and women. *Acta Oncol*. 2018 Jun 18:1-11. doi: 10.1080/0284186X.2018.1481293. [Epub ahead of print]  
Impactfactor: 3,473

Ortmann O, Helbig U, Torode J, Schreck S, Karjalainen S, Bettio M, Ringborg U, Klinkhammer-Schalke M, Bray F; participants of the ER (**Siesling S**). Quality control and improvement of cancer care: what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin, Germany. *J Cancer Res Clin Oncol*. 2018 Jun;144(6):1097-1102. doi: 10.1007/s00432-018-2638-0. Epub 2018 Apr 9. Review.  
Impactfactor: 3,282

Pearce A, Tomalin B, Kaambwa B, **Horevoorts N**, Duijts S, **Mols F**, **van de Poll-Franse L**, Koczwara B. Financial toxicity is more than costs of care: the relationship between employment and financial toxicity in long-term cancer survivors. *J Cancer Surviv*. 2018 Oct 24. doi: 10.1007/s11764-018-0723-7. [Epub ahead of print]  
Impactfactor: 3,713

**Raijmakers NJ**, **Zijlstra M**, **van Roij J**, Husson O, **Oerlemans S**, **van de Poll-Franse LV**. Health-related quality of life among cancer patients in their last year of life: results from the PROFILES registry. *Support Care Cancer*. 2018 Apr 16. doi: 10.1007/s00520-018-4181-6. [Epub ahead of print]  
Impactfactor: 2,676

**Raijmakers NJ**, de Veer AJ, Zwaan R, Hofstede JM, Francke AL. Which patients die in their preferred place? A secondary analysis of questionnaire data from bereaved relatives. *Palliat Med*. 2018 Feb;32(2):347-356. doi: 10.1177/0269216317710383.  
Impactfactor: 3,780

Schmidt SAJ, Lo S, **Hollestein LM**. Research Techniques Made Simple: Sample Size Estimation and Power Calculation. *J Invest Dermatol*. 2018 Aug;138(8):1678-1682. doi: 10.1016/j.jid.2018.06.165.  
Impactfactor: 6,448

Schoormans D, **Visser PA**, van Herk-Sukel MP, Denollet J, Pedersen SS, Dalton SO, Rottmann N, **van de Poll-Franse LV**. Incidence of cardiovascular disease up to 13 year after cancer diagnosis: A matched cohort study among 32 757 cancer survivors. *Cancer Med*. 2018 Sep 15. doi: 10.1002/cam4.1754. [Epub ahead of print]  
Impactfactor: 3,202

Schoormans D, Verhoeven JE, Denollet J, **van de Poll-Franse LV**, Penninx BW. Leukocyte telomere length and personality: associations with the Big Five and Type D personality traits. *Psychol Med*. 2018 Apr;48(6):1008-1019. doi: 10.1017/S0033291717002471. Epub 2017 Sep 11.  
Impactfactor: 5,475

**Schroten-Loef C**, **Verhoeven RH**, de Hingh IH, van de Wouw AJ, van Laarhoven HW, **Lemmens VE**. Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012. *Eur J Cancer*. 2018 Jul 19;101:77-86. doi: 10.1016/j.ejca.2018.06.032. [Epub ahead of print]  
Impactfactor: 7,191



Schrijnders D, Hendriks SH, Kleefstra N, **Vissers PA**, Johnson JA, de Bock GH, Bilo HJ, Landman GW. Sex differences in obesity related cancer incidence in relation to type 2 diabetes diagnosis (ZODIAC-49). PLoS One. 2018 Jan 25;13(1):e0190870. doi: 10.1371/journal.pone.0190870. eCollection 2018. Impactfactor: 2,766

Steliarova-Foucher E, Fidler MM, Colombet M, Lacour B, Kaatsch P, Piñeros M, Soerjomataram I, Bray F, Coebergh JW, Peris-Bonet R, Stiller CA; ACCIS contributors (**Visser O**). Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991-2010 (Automated Childhood Cancer Information System): a population-based study. Lancet Oncol. 2018 Sep;19(9): 1159-1169. doi: 10.1016/S1470-2045(18)30423-6. Epub 2018 Aug 8. Impactfactor: 36,421

Swaen GM, Langendam M, Weyler J, Burger H, **Siesling S**, Atsma WJ, Bouter L. Responsible Epidemiologic Research Practice: a guideline developed by a working group of the Netherlands Epidemiological Society. J Clin Epidemiol. 2018 Feb 10. pii: S0895-4356(17)30465-1. doi: 10.1016/j.jclinepi.2018.02.010. [Epub ahead of print] Impactfactor: 4,245

Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, **Velthuis MJ**, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM. Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. Br J Sports Med. 2018 Sep 4. pii: bjsports-2018-099191. doi: 10.1136/bjsports-2018-099191. [Epub ahead of print] Review. Impactfactor: 7,867

Tähtinen RM, Cartwright R, **Vernooij RW**, Rortveit G, Hunskar S, Guyatt GH, Tikkinen KA. Long-term risks of stress and urgency urinary incontinence after different vaginal delivery modes. Am J Obstet Gynecol. 2018 Oct 31. pii: S0002-9378(18)30941-4. doi: 10.1016/j.ajog.2018.10.034. [Epub ahead of print] Impactfactor: 5,732

**van Eenbergen MC**, **van de Poll-Franse LV**, Kraemer E, Verberne S, **Mols F**. Analysis of Content Shared in Online Cancer Communities: Systematic Review. JMIR Cancer. 2018 Apr 3;4(1):e6. doi: 10.2196/cancer.7926. Review. Impactfactor: 4,671

**van Eenbergen MC**, van Engelen H, **Ezendam NP**, **van de Poll-Franse LV**, Tates K, Kraemer EJ. Paying attention to relatives of cancer patients: What can we learn from their online writings? Patient Educ Couns. 2018 Nov 10. pii: S0738-3991(18)30972-8. doi: 10.1016/j.pec.2018.11.004. [Epub ahead of print] Impactfactor: 2,785

van Esch HJ, van Zuylen L, Oomen-de Hoop E, van der Heide A, **van der Rijt CC**. Scopolaminebutyl given prophylactically for death rattle: study protocol of a randomized double-blind placebo-controlled trial in a frail patient population (the SILENCE study). BMC Palliat Care. 2018 Sep 7;17(1):105. doi: 10.1186/s12904-018-0359-4. Impactfactor: 2,335

van Leeuwen M, Husson O, Alberti P, Arraras JI, Chinot OL, Costantini A, Darlington AS, Dirven L, Eichler M, Hammerlid EB, Holzner B, Johnson CD, Kontogianni M, Kjær TK, Morag O, Nolte S, Nordin A, Pace A, Pinto M, Polz K, Ramage J, Reijneveld JC, Serpentine S, Tomaszewski KA, Vassiliou V, Verdonck-de Leeuw IM, Vistad I, Young TE, Aaronson NK, **van de Poll-Franse LV**; EORTC QLQ. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes. 2018 Jun 4;16(1):114. doi: 10.1186/s12955-018-0920-0. Impactfactor: 2,278

van Nuenen FM, Donofrio SM, van de Wiel HB, **Hoekstra-Weebbers JE**. Cancer patients' experiences with and opinions on the process 'Screening of Distress and Referral Need' (SDRN) in clinical practice: A quantitative observational clinical study. *PLoS One*. 2018 Jun 14;13(6):e0198722. doi: 10.1371/journal.pone.0198722. eCollection 2018. Impactfactor: 2,766

**van Roij J, Fransen H, van de Poll-Franse LV, Zijlstra M, Raijmakers N**. Measuring health-related quality of life in patients with advanced cancer: a systematic review of self-administered measurement instruments. *Qual Life Res*. 2018 Feb 10. doi: 10.1007/s11136-018-1809-4. [Epub ahead of print] Review. Impactfactor: 2,392

**van Roij J, Brom L, Youssef-EI Soud M, van de Poll-Franse LV, Raijmakers NJ**. Social consequences of advanced cancer in patients and their informal caregivers: a qualitative study. *Support Care Cancer*. 2018 Sep 13. doi: 10.1007/s00520-018-4437-1. [Epub ahead of print] Impactfactor: 2,676

**van Veen MR, Winkels RM, Janssen SH, Kampman E, Beijer S**. Nutritional Information Provision to Cancer Patients and Their Relatives Can Promote Dietary Behavior Changes Independent of Nutritional Information Needs. *Nutr Cancer*. 2018 Mar 14:1-7. doi: 10.1080/01635581.2018.1446092. [Epub ahead of print] Impactfactor: 2,261

Vermandere M, Kuijpers T, Burgers JS, Kunnamo I, van Lieshout J, Wallace E, Vlayen J, Schoenfeld E, Siemieniuk RA, Trevena L, Zhu X, Verermen F, Neuschwander B, Dahm PH, Tikkinen KA, Aubrey-Bassler K, **Vernooij RW**, Aertgeerts B, Bekkering GE. Alpha-blockers for uncomplicated ureteral stones: a clinical practice guideline. *BJU Int*. 2018 Jul 11. doi: 10.1111/bju.14457. [Epub ahead of print] Impactfactor: 4,688

Witlox L, Hiensch AE, **Velthuis MJ**, Steins Bisschop CN, Los M, Erdkamp FL, Bloemendal HJ, Verhaar M, Ten Bokkel Huinink D, van der Wall E, Peeters PH, May AM. Four-year effects of exercise on fatigue and physical activity in patients with cancer. *BMC Med*. 2018 Jun 8;16(1):86. doi: 10.1186/s12916-018-1075-x. Impactfactor: 9,088

## 1.2 Overige publicaties

**Rolf CA, Cost Budde P, van Heest F, Schuit K**. Als problemen optreden bij palliatieve sedatie: overwegingen bij sedatie in de terminale fase. *Ned Tijdsch Geneesk* 2018 Mei 12:162(19);32-35.

Simancas-Racines D, Montero-Oleas N, **Vernooij RW**, Arevalo-Rodriguez I, Fuentes P, Gich I, Hidalgo R, Martinez-Zapata MJ, Bonfill X, Alonso-Coello P. Quality of clinical practice guidelines about red blood cell transfusion. *J Evid Based Med*. 2018 Dec 3. doi: 10.1111/jebm.12330. [Epub ahead of print]

Thong MS, **Mols F**, Doege D, **van de Poll-Franse LV**, Arndt V. Population-based cancer survivorship research: experiences from Germany and the Netherlands. *Journal of Cancer Policy*. 2018 May;5:87-91. doi: 10.1016/j.jcpo.2018.02.003.

**van Hove JC, Vernooij RW**, Lawal AK, Fiander M, Nieboer P, **Siesling S**, Rotter T. Effects of oncological care pathways in primary and secondary care on patient, professional, and health systems outcomes: protocol for a systematic review and meta-analysis. *Syst Rev*. 2018 Mar 27;7(1):49. doi: 10.1186/s13643-018-0693-x.

## 1.3 Boekbijdragen

Boyle FM, Shaw J, Young A, **van den Hurk CJ**, Rugo HS, Fogarty GB, Lacouture ME. Management of alopecia due to cancer therapies. In: *The MASCC Textbook of Cancer Supportive Care and Survivorship / I. Olver (ed.)*. Springer : Cham, 2018.

## 1.4 Proefschriften en promoties

**Vernooij RW**. Updated clinical guidelines: improving their methods and reporting. Barcelona: Universitat Autònoma de Barcelona; 16 februari 2018. Promotoren: P Alonso-Coello en LM García.

## 1.5 Posters

**Brom L**, van Riet Paap J, Engels Y, de Nijs E, van der Linden Y, **Fransen H**. Palliative care needs of patients with lung or colorectal cancer in Dutch hospitals. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

**de Rooij BH**, Park ER, Pereze GK, Rabin J, Quain KM, Dizon DS, Post KE, Chinn G, McDonough A, Jimenez R, **van de Poll-Franse LV**. Cluster analysis to demonstrate the need to individualize care for cancer survivors. Cancer Survivorship Symposium; 16-17 februari 2018; Orlando.

**Ebben K**, Lamb P, **van der Werf J**, Hendriks M, Skinner J, **Vernooij RW**, Keikes L, **Verbeek X**. A method for structured comparison of clinical practice guidelines applied to NCCN and Dutch oncological guidelines. NCCN Annual Conference; 22-24 maart 2018; Orlando.

**Ebben K**, Hendriks M, **van Veghel T**, **van der Werf J**, van der Sangen M, Keikes L, **Verbeek X**. A novel method for clinical and computer interpretable presentation of clinical practice guidelines by non probabilistic data driven decision trees. NCCN Annual Conference; 22-24 maart 2018; Orlando.

**Ezendam NP**, Karlsen RV, Christensen J, Tjønneland A, **van de Poll-Franse LV**, von Heymann-Horan A, Johansen C, Bidstrup PE. Do people improve health behavior after their partner is diagnosed with cancer?: a Danish cohort study. ECRS, European Cancer Rehabilitation & Survivorship Symposium; 10-11 september 2018; Kopenhagen.

Husson O, **de Rooij BH**, Kieffer JM, Oerlemans S, Mols F, Aaronson NK, van der Graaf WT, **van de Poll-Franse LV**. Independent prognostic value of the EORTC QIQ-C30 summary score on all-cause mortality: results from the population-based PROFILES registry. ASCO Annual Meeting; 1-5 juni 2018; Chicago.

Liu L, Neven A, Maraldo MV, Giusti F, Fortpied C, Collette L, **Visser O**. Cancer clinical research should join forces with registries on long-term outcome research: a showcase of EORTC-IKNL. ENCR, European Network of Cancer Registries Scientific Meeting and General Assembly; 26-28 september 2018; Kopenhagen.

**Siesling S**, **van der Weide W**, **Verbeek X**, Schade K, **Schreuder K**, **Verhoeven RH**, **van Veghel T**, **Visser O**, **Verloop J**, **Lemmens VE**. Quality improvement by online insight in the Netherlands Cancer Registry. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

Trama A, Gatta G, van Eycken L, **Visser O**, Chirlaque-Lopez MD, Navarro-Sanchez C, Marcos-Gragera R, Walsh P, López-Briones C, Capocaccia R. Improving registration of rare cancers: the proposal of the JIONT Action on Rare Cancers (JARC). ENCR, European Network of Cancer Registries Scientific Meeting and General Assembly; 26-28 september 2018; Kopenhagen.

**van den Hurk CJ**, Young A, Nangia JR, Rugo HS, Lacouture ME, Boyle F. Chill group monitors the incidence of chemotherapy-induced alopecia with and without scalp cooling. MASCC/ISOO annual meeting; 28-30 juni 2018; Wenen.

**van Roij J**, **Raijmakers NJ**, Youssef-EI Soud, M, **van de Poll-Franse LV**, **Brom L**. Social consequences of advanced cancer in patients and their informal caregivers: a qualitative study. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

**van Steenbeek C**, **van Maaren MC**, **Siesling S**, **Witteveen A**, Mentink R, Pleihuis R, **Verbeek X**, Koffijberg H. Validation of prediction models: a comparison of manual and semi-automated validation using cancer registry data. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

## 1.6 Presentaties en abstracts

Adam S, **Mols F**, Arndt V, **Ezendam NP**, **van de Poll-Franse LV**, Thong MS. The association of cancer-related fatigue with all-cause mortality of colorectal and endometrial cancer survivors: a population-based study. MASCC/ISOO annual meeting; 28-30 juni 2018; Wenen.

Adam S, **Mols F**, **Ezendam NP**, Thong MS. The association of cancer-related fatigue with overall survival of colorectal and endometrial cancer survivors: a population-based study. Deutscher Krebskongress; 21-24 februari 2018; Berlijn.

**Brom L**, Engels Y, van Riet Paap J, de Nijs E, van der Linden Y, **Fransen H**. Palliative care need of patients with lung or colorectal cancer in Dutch hospitals. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

de Man Y, Atsma F, Oosterveld-Vlug M, **Brom L**, Westert G, Groenewoud S. High intensity of healthcare utilisation in the last phase of life of Dutch lung cancer and colorectal cancer patients. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

de Heij A, van der Stap L, van der Heide A, Engels Y, **Fransen H**, Janssen D, Teunissen S, van Weert H, van Linde M, van der Linden Y, Reyners A. A multidimensional strategy to improve quality of life in patients with multiple symptoms and palliative care needs: the development of the MuSt-PC. International congress on palliative care; 2-5 oktober 2018; Montréal.

**Ebben K**, Lamb P, **van der Werf J**, Hendriks M, Skinner J, **Vernooij RW**, Keikes L, **Verbeek X**. A method for structured comparison of oncologic clinical practice guidelines. NCCN Annual Conference; 22-24 maart 2018; Orlando.

**Ezendam NP**, Karlsen RV, Christensen J, Tjønneland A, **van de Poll-Franse LV**, von Heymann-Horan A, Johansen C, Bidstrup PE. Do people improve health behavior after their partner is diagnosed with cancer?: a Danish cohort study. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

**Ezendam NP**, Karlsen RV, Christensen J, Tjønneland A, **van de Poll-Franse LV**, von Heymann-Horan A, Johansen C, Bidstrup PE. Do people improve health behavior after their partner is diagnosed with cancer?: a Danish cohort study. MASCC/ISOO annual meeting; 28-30 juni 2018; Wenen.

**Geleijnse G**, **Sieswerda M**, **Schuurman MS**, Chiang R, **van der Zalm A**, Lee KC, van Soest J, Deist T, Dekker A, **Verbeek X**. Distributedlearning.ai: towards a distributed learning network for cancer registries. ENCR, European Network of Cancer Registries Scientific Meeting and General Assembly; 26-28 september 2018; Kopenhagen.

**Raijmakers NJ**, **Zijlstra M**, **van Roij J**, Husson O, **Oerlemans S**, **van de Poll-Franse LV**. Health-related quality of life among cancer patients in their last year of life. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

Schoormans D, Pedersen S, Dalton S, Rottmann N, **van de Poll-Franse LV**. Cardiovascular co-morbidity in cancer patients: the role of psychological distress. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

**Schuurman MS**, **Geleijnse G**, Chiang R, **van der Zwan JM**, Sieswerda M, Deist T, van Soest J, Lee KC, Dekker A, **Verbeek X**. Towards a distributed learning network for cancer registries. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

**van den Hurk CJ**, Young A, Nangia JR, Rugo HS, Lacouture ME, Boyle F. Chill group monitors the incidence of chemotherapy-induced alopecia with and without scalp cooling. MASCC/ISOO annual meeting; 28-30 juni 2018; Wenen.

van der Stap L, de Heij AH, van der Heide A, Engels Y, **Fransen H**, Janssen DJ, Teunissen SC, van Weert HC, van Linde M, Reyners AK, van der Linden YM. A multidimensional strategy to improve quality of life in patients with multiple symptoms and palliative care needs: the development of the MuSt-PC. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

**van der Zwan JM, Blaauwgeers H, Ho VK, van Maaren MC, Kwast A.** Rare cancer care lags behind: recommendations to guide policy-making based on the Netherlands Cancer Registry. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

van Riet Paap J, Vissers K, Schers H, Perry M, Blom H, **Brom L**, Douma J, van der Linden Y, Verhagen S, Engels Y. When to consider expert palliative care consultation for patients with advanced cancer: development of a set of triggers. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

**van Roij J.** Social consequences of advanced cancer in patients and their informal caregivers. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

van Steenbeek CD, **van Maaren MC, Siesling S**, Witteveen A, **Verbeek X**, Koffijberg H. Facilitating validation of prediction models: a comparison of manual and semi-automated validation using registry-based data. WEON Congres, Werkgroep Epidemiologisch Onderzoek Nederland; 7-8 juni 2018; Bilthoven.

**van Veen M**, Kampman E, Kolen B, **Beijer S**. Empowering oncology nurses in providing nutritional information to cancer survivors. MASCC/ISOO annual meeting; 28-30 juni 2018; Wenen.

**Wauven B, Timmermans H, Ho VK, Verhoeven RH, Siesling S, Lemmens VE, Visser O.** Estimating complete cancer incidence in the absence of death certificate notifications: the Netherlands Cancer Registry. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

## 2 Borstkanker

### 2.1 Publicaties met impactfactor

Catsman CJ, Beek MA, **Voogd AC**, Mulder PG, Luiten EJ. The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery. *BMC Cancer*. 2018 Apr 23;18(1):456. doi: 10.1186/s12885-018-4368-8. Impactfactor: 3,288

Coolen AM, Lameijer JR, **Voogd AC**, **Louwman MW**, Strobbe LJ, Tjan-Heijnen VC, Duijm LE. Characteristics of screen-detected cancers following concordant or discordant recalls at blinded double reading in biennial digital screening mammography. *Eur Radiol*. 2018 Jun 25. doi: 10.1007/s00330-018-5586-9. [Epub ahead of print] Impactfactor: 4,027

Coolen AM, **Voogd AC**, Strobbe LJ, **Louwman MW**, Tjan-Heijnen VC, Duijm LE. Impact of the second reader on screening outcome at blinded double reading of digital screening mammograms. *Br J Cancer*. 2018 Jul 24. doi: 10.1038/s41416-018-0195-6. [Epub ahead of print] Impactfactor: 5,922

Coolen AM, Lameijer JR, **Voogd AC**, Strobbe LJ, **Louwman MW**, Tjan-Heijnen VC, Duijm LE. Incorporation of the technologist's opinion for arbitration of discrepant assessments among radiologists at screening mammography. *Breast Cancer Res Treat*. 2018 May 5. doi: 10.1007/s10549-018-4800-4. [Epub ahead of print] Impactfactor: 3,605

**de Ligt KM**, Witteveen A, **Siesling S**, Steuten LM. Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study. *BMC Cancer*. 2018 Jan 24;18(1):96. doi: 10.1186/s12885-018-3992-7. Impactfactor: 3,288

**de Ligt KM**, van Bommel AC, **Schreuder K**, Maduro JH, Vrancken Peeters MT, Mureau MA, **Siesling S**; NABON Breast Cancer Audit Working Group. The effect of being informed on receiving immediate breast reconstruction in breast cancer patients. *Eur J Surg Oncol*. 2018 Feb 2. pii: S0748-7983(18)30275-0. doi: 10.1016/j.ejso.2018.01.226. [Epub ahead of print] Impactfactor: 3,688

**de Munck L**, Fracheboud J, de Bock GH, den Heeten GJ, **Siesling S**, Broeders MJ. Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program? *Int J Cancer*. 2018 Mar 25. doi: 10.1002/ijc.31388. [Epub ahead of print] Impactfactor: 7,360

Derks MG, Bastiaannet E, Kiderlen M, Hilling DE, Boelens PG, Walsh PM, van Eycken E, **Siesling S**, Broggio J, Wyld L, Trojanowski M, Kolacinska A, Chalubinska-Fendler J, Gonçalves AF, Nowikiewicz T, Zegarski W, Audisio RA, Liefers GJ, Portielje JE, van de Velde CJ; EURECCA Breast Cancer Group. Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group. *Br J Cancer*. 2018 Jun 7. doi: 10.1038/s41416-018-0090-1. [Epub ahead of print] Impactfactor: 5,922

Heeg E, **Schreuder K**, Spronk PE, Oosterwijk JC, Marang-van de Mheen PJ, **Siesling S**, Peeters MT; NABON Breast Cancer Audit. Hospital transfer after a breast cancer diagnosis: A population-based study in the Netherlands of the extent, predictive characteristics and its impact on time to treatment. *Eur J Surg Oncol*. 2018 Dec 29. pii: S0748-7983(18)32039-0. doi: 10.1016/j.ejso.2018.12.017. [Epub ahead of print] Impactfactor: 3,688



Jobsen JJ, Middelburg JG, van der Palen J, Riemersma S, Siemerink E, Struikmans H, **Siesling S**. Breast-conserving therapy in older patients with breast cancer over three decades: progress or stagnation. *J Geriatr Oncol*. 2018 Aug 18. pii: S1879-4068(18)30123-1. doi: 10.1016/j.jgo.2018.08.007. [Epub ahead of print]  
Impactfactor: 3,359

Komen MM, **van den Hurk CJ**, Nortier JW, van der Ploeg T, Nieboer P, van der Hoeven JJ, Smorenburg CH. Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy. *Support Care Cancer*. 2018 Sep 11. doi: 10.1007/s00520-018-4432-6. [Epub ahead of print]  
Impactfactor: 2,676

Lameijer JR, Coolen AM, **Voogd AC**, Strobbe LJ, **Louwman MW**, Venderink D, Tjan-Heijnen VC, Duijm LE. Correction to: Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography. *Eur Radiol*. 2018 Jun 25. doi: 10.1007/s00330-018-5532-x. [Epub ahead of print]  
Impactfactor: 4,027

Lameijer JR, Coolen AM, Nederend J, **Voogd AC**, Tjan-Heijnen VC, Duijm LE. Frequency and characteristics of additionally detected ipsilateral breast lesions following recall at screening mammography. *Breast*. 2018 Aug 28;42:94-101. doi: 10.1016/j.breast.2018.08.104. [Epub ahead of print]  
Impactfactor: 2,951

Lameijer JR, Coolen AM, **Voogd AC**, Strobbe LJ, **Louwman MW**, Venderink D, Tjan-Heijnen VC, Duijm LE. Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography. *Eur Radiol*. 2018 Apr 17. doi: 10.1007/s00330-018-5370-x. [Epub ahead of print] Erratum in: *Eur Radiol*. 2018 Jun 25.  
Impactfactor: 4,027

Meurs CJ, van Rosmalen J, Menke-Pluijmers MB, Ter Braak BP, **de Munck L**, **Siesling S**, Westenend PJ. A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers. *Br J Cancer*. 2018 Oct 17. doi: 10.1038/s41416-018-0276-6. [Epub ahead of print]  
Impactfactor: 5,922

Poodt IG, Vugts G, Maaskant-Braat AJ, Schipper RJ, **Voogd AC**, Nieuwenhuijzen GA; Sentinel Node and Recurrent Breast Cancer (SNARB) study group. Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence. *Ann Surg Oncol*. 2018 Mar 1. doi: 10.1245/s10434-018-6384-y. [Epub ahead of print]  
Impactfactor: 3,857

Poodt IG, Schipper RJ, Vugts G, Woensdregt K, van der Sangen M, **Voogd AC**, Nieuwenhuijzen GA. The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer. *Eur J Surg Oncol*. 2018 Jul 27. pii: S0748-7983(18)31184-3. doi: 10.1016/j.ejso.2018.07.005. [Epub ahead of print]  
Impactfactor: 3,688

Qiu SQ, Aarnink M, **van Maaren MC**, Dorrius MD, Bhattacharya A, Veltman J, Klazen CA, Korte JH, Estourgie SH, Ott P, Kelder W, Zeng HC, Koffijberg H, Zhang GJ, van Dam GM, **Siesling S**. Validation and update of a lymph node metastasis prediction model for breast cancer. *Eur J Surg Oncol*. 2018 Jan 17. pii: S0748-7983(18)30037-4. doi: 10.1016/j.ejso.2017.12.008. [Epub ahead of print]  
Impactfactor: 3,688

Roos MM, van Steenhoven JE, Aalders KC, **Schreuder K**, Burgmans JP, **Siesling S**, Elias S, van Dalen T. Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment. *Ann Surg Oncol*. 2018 Nov 1. doi: 10.1245/s10434-018-6940-5. [Epub ahead of print]  
Impactfactor: 3,857

Ruiz A, van Hillegerberg R, **Siesling S**, Castro-Benitez C, Sebahg M, Wicherts DA, **de Ligt KM**, Goense L, Giacchetti S, Castaing D, Morère J, Adam R. Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison. *Eur J Cancer*. 2018 Mar 23;95:1-10. doi: 10.1016/j.ejca.2018.02.024. [Epub ahead of print]  
Impactfactor: 7,191

Samiei S, van Nijnatten TJ, **de Munck L**, Keymeulen KB, Simons JM, Kooreman LF, **Siesling S**, Lobbes MB, Smidt ML. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. *Ann Surg*. 2018 Dec 13. doi: 10.1097/SLA.0000000000003126. [Epub ahead of print]  
Impactfactor: 9,203

Sankatsing VD, Fracheboud J, **de Munck L**, Broeders MJ, van Ravesteyn NT, Heijnsdijk EA, Verbeek AL, Otten JD, Pijnappel RM, **Siesling S**, de Koning HJ; National Evaluation Team for Breast cancer screening, NETB. Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening. *BMC Cancer*. 2018 Mar 5;18(1):256. doi: 10.1186/s12885-018-4122-2.  
Impactfactor: 3,288

**Schreuder K**, Maduro JH, Spronk PE, Bijker N, Poortmans PM, van Dalen T, Struikmans H, **Siesling S**. Variation in the Use of Boost Irradiation in Breast-Conserving Therapy in the Netherlands: The Effect of a National Guideline and Cofounding Factors. *Clin Oncol (R Coll Radiol)*. 2018 Dec 8. pii: S0936-6555(18)30529-6. doi: 10.1016/j.clon.2018.11.033. [Epub ahead of print]  
Impactfactor: 3,055

Spronk PE, **de Ligt KM**, van Bommel AC, **Siesling S**, Smorenburg CH, Vrancken Peeters MT; NABON Breast Cancer Audit. Current decisions on neoadjuvant chemotherapy for early breast cancer: Experts' experiences in the Netherlands. *Patient Educ Couns*. 2018 Dec;101(12):2111-2115. doi: 10.1016/j.pec.2018.07.012. Epub 2018 Jul 18.  
Impactfactor: 2,785

van Bommel AC, **Schreuder K**, Veenstra RK, **de Ligt KM**, Vrancken Peeters MT, Maduro JH, **Siesling S**, Mureau MA. Discrepancies Between Surgical Oncologists and Plastic Surgeons in Patient Information Provision and Personal Opinions Towards Immediate Breast Reconstruction. *Ann Plast Surg*. 2018 Jul 31. doi: 10.1097/SAP.0000000000001572. [Epub ahead of print]  
Impactfactor: 1,536

van Bommel RM, **Voogd AC**, Nederend J, Setz-Pels W, **Louwman MW**, Strobbe LJ, Venderink D, Tjan-Heijnen VC, Duijm LE. Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography. *Breast*. 2018 Jan 3;38:101-106. doi: 10.1016/j.breast.2017.12.018. [Epub ahead of print]  
Impactfactor: 2,951

van Bommel RM, Lameijer JR, **Voogd AC**, Nederend J, **Louwman MW**, Setz-Pels W, Strobbe LJ, Tjan-Heijnen VC, Duijm LE. Tumour characteristics of bilateral screen-detected cancers and bilateral interval cancers in women participating at biennial screening mammography. *Eur J Radiol*. 2018 Nov;108:215-221. doi: 10.1016/j.ejrad.2018.09.026. Epub 2018 Sep 24.  
Impactfactor: 2,843

van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HS, Rutgers EJ, Russell NS, Smit VT, **Voogd AC**, Koppert LB, **Siesling S**, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar RA. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. *Ann Surg*. 2018 May 1. doi: 10.1097/SLA.0000000000002804. [Epub ahead of print]  
Impactfactor: 9,203

van Hellemond IE, Vriens IJ, Peer PG, **Swinkels AC**, Smorenburg CH, Seynaeve CM, van der Sangen MJ, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FL, van den Berkmoortel FW, de Boer M, de Roos WK, Linn SC, Imholz AL, Tjan-Heijnen VC; Dutch Breast Cancer Research Group (BOOG). Efficacy of Anastrozole after Tamoxifen in Early Breast Cancer Patients with Chemotherapy-Induced Ovarian Function Failure. *Int J Cancer*. 2018 Dec 26. doi: 10.1002/ijc.32093. [Epub ahead of print]  
Impactfactor: 7,36



**van Maaren MC**, Lagendijk M, Tilanus-Linthorst MM, **de Munck L**, Pijnappel RM, Schmidt MK, Wesseling J, Koppert LB, **Siesling S**. Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012. *Eur J Cancer*. 2018 Jul 27;101:134-142. doi: 10.1016/j.ejca.2018.07.003. [Epub ahead of print]  
Impactfactor: 7,191

**van Maaren MC**, Strobbe LJ, Koppert LB, Poortmans PM, **Siesling S**. Nationwide population-based study of trends and regional variation in breast-conserving treatment for breast cancer. *Br J Surg*. 2018 Aug 9. doi: 10.1002/bjs.10951. [Epub ahead of print]  
Impactfactor: 5,433

**van Maaren MC**, Strobbe LJ, Smidt ML, Moosdorff M, Poortmans PM, **Siesling S**. Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years. *Eur J Cancer*. 2018 Aug 22;102:82-94. doi: 10.1016/j.ejca.2018.07.124. [Epub ahead of print]  
Impactfactor: 7,191

**van Maaren MC**, **de Munck L**, Strobbe LJ, Sonke GS, Westenend PJ, Smidt ML, Poortmans PM, **Siesling S**. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. *Int J Cancer*. 2018 Oct 28. doi: 10.1002/ijc.31914. [Epub ahead of print]  
Impactfactor: 7,360

van Steenhoven JE, Kuijer A, van Diest PJ, van Gorp JM, Straver M, Elias SG, Wesseling J, Rutgers E, Timmer-Bonte JN, Nieboer P, Smilde TJ, Imholz A, Blanken CF, **Siesling S**, van Dalen T. Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. *Genes (Basel)*. 2018 May 17;9(5). pii: E261. doi: 10.3390/genes9050261.  
Impactfactor: 3,191

Vugts G, Van den Heuvel F, Maaskant-Braat AJ, **Voogd AC**, Van Warmerdam LJ, Nieuwenhuijzen GA, Van der Sangen MJ. Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status. *Breast J*. 2018 Jul 22. doi: 10.1111/tbj.13085. [Epub ahead of print]  
Impactfactor: 2,424

Witteveen A, Nane GF, Vliegen IM, **Siesling S**, IJzerman MJ. Comparison of Logistic Regression and Bayesian Networks for Risk Prediction of Breast Cancer Recurrence. *Med Decis Making*. 2018 Aug 22;272989X18790963. doi: 10.1177/0272989X18790963. [Epub ahead of print]  
Impactfactor: 3,012

Witteveen A, Otten JW, Vliegen IM, **Siesling S**, Timmer JB, IJzerman MJ. Risk-based breast cancer follow-up stratified by age. *Cancer Med*. 2018 Sep 11. doi: 10.1002/cam4.1760. [Epub ahead of print]  
Impactfactor: 3,202

## 2.2 Proefschriften en promoties

Jeeninga-Witteveen A. Influence: individualized follow-up for breast cancer. Enschede: Universiteit Twente; 2 november 2018. Promotoren: MJ IJzerman, **S Siesling**.

**Schreuder K**. Monitoring evolving breast cancer care: reconstructive surgery, radiotherapy and gene profiling. Enschede: Universiteit Twente; 6 juli 2018. Promotoren: **S. Siesling**, H. Struikmans. Co-promotor: Th. van Dalen. Commissieleden: TA. Toonen, EW Hans, GC Kusters, **VE Lemmens**, EJ Rutgers, A Jager, HA Rakhorst.

**van Maaren MC**. Local management of early stage breast cancer and clinical risk prediction of survival. Enschede: Universiteit Twente; 28 september 2018. Promotoren: **S. Siesling**, PM. Poortmans.

Vos EL. Tying a Surgical Knot in Breast Cancer Outcomes. Rotterdam: Erasmus Universiteit; 6 november 2018. Promotoren: C Verhoef, **S Siesling**.

Weber RJ. Digital breast cancer screening: interval cancer and reading strategies. Maastricht: Universiteit Maastricht; 21 december 2018. Promotor: VC Tjan-Heijnen. Copromotoren: LE Duijm, **AC Voogd, WJ Louwman**.

## 2.3 Posters

Abbas S, Jobsen JJ, van der Valk P, Heuvelmans M, Heijmans HJ, Struikmans H, van der Palen J, **Siesling S**. Pulmonary complications in breast cancer survivors: long-term effects of adjuvant treatment? EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**de Ligt KM**, Heins M, Beldhuis E, **Verloop J, Siesling S**, Korevaar J. Patient-reported quality of life and late effects for breast cancer patients up to five year after treatment. WEON Congres, Werkgroep Epidemiologisch Onderzoek Nederland; 7-8 juni 2018; Bilthoven.

**de Munck L, Siesling S**. Monitoring the Dutch breast cancer screening program. WEON Congres, Werkgroep Epidemiologisch Onderzoek Nederland; 7-8 juni 2018; Bilthoven.

**de Munck L, van Maaren MC**, Strobbe LJ, Smidt ML, Poortmans PM, **Siesling S**. Ten-year recurrence risk for molecular subtypes in breast cancer: a large population-based study in the Netherlands. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**Hendriks M, van Vegchel T**, van der Sangen M, **Ebben K, Siesling S, Verbeek X**. Clinical practice guidelines in the era of data driven personalized cancer treatment. NCCN Annual Conference; 22-24 maart 2018; Orlando.

Huetting TA, Tip BC, Mentink RJ, Koffijberg H, **Siesling S**. Clinical risk prediction models for breast cancer: a review of models developed between 2010 and 2018. San Antonio Breast Cancer Symposium; 4-8 december 2018; San Antonio, Texas.

Samiei S, van Nijnatten T, **de Munck L**, Keymeulen K, Simons J, Kooreman L, **Siesling S**, Lobbes M, Smidt M. Positive correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**Schreuder K**, Kuijer A, Bentum S, van Dalen T, **Siesling S**. Use and impact of the 21-gene recurrence score in relation to the clinical risk of developing metastases in early breast cancer patients in the Netherlands. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**Schreuder K**, Kuijer A, Bentum S, van Dalen T, **Siesling S**. Use of 21-gene recurrence score in relation to the clinical risk in breast cancer patients. Conferentie Supporting Health by Technology; 1 juni 2018; Enschede.

**Schreuder K**, Maduro JH, Spronk P, Bijker N, Poortmans PM, van Dalen T, Struikmans H, **Siesling S**. Variation in the use of boost irradiation in breast conserving therapy in the Netherlands. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**Schreuder K**, Maduro JH, Spronk P, Bijker N, Poortmans PM, Struikmans H, **Siesling S**. Variation in the use of boost irradiation in breast conserving therapy in the Netherlands. Conferentie Supporting Health by Technology; 1 juni 2018; Enschede.

**van Maaren MC**, Lagendijk M, Tilanus-Linthorst MM, **de Munck L**, Schmidt MK, Wesseling J, Koppert LB, **Siesling S**. Breast cancer-related deaths according to grade in ductal carcinoma in situ: a Dutch population-based study. WEON Congres, Werkgroep Epidemiologisch Onderzoek Nederland; 7-8 juni 2018; Bilthoven.

**van Maaren MC**, Lagendijk M, Tilanus-Linthorst MM, **de Munck L**, Pijnappel RM, Schmidt MK, Wesseling J, Koppert LB, **Siesling S**. Breast cancer-related deaths according to grade in ductal carcinoma in situ: a Dutch population-based study on patients diagnosed between 1999 and 2012. San Antonio Breast Cancer Symposium; 4-8 december 2018; San Antonio, Texas.

**van Maaren MC**, Strobbe LJ, Smidt ML, Moosdorff M, Poortmans PM, **Siesling S**. Ten-year conditional recurrence risks, overall and relative survival for breast cancer patients in the Netherlands: taking account of event-free years. San Antonio Breast Cancer Symposium; 4-8 december 2018; San Antonio, Texas.

**van Maaren MC**, Strobbe LJ, Koppert LB, Poortmans PM, **Siesling S**. Time trends and regional variation in breast-conserving treatment in the Netherlands: a nationwide population-based study. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**Verloop J**, Heins M, **de Ligt KM**, Korevaar J, **Siesling S**. Primary and secondary cancer care registry: long term effects of breast cancer treatments. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

**Verloop J**, Heins M, **de Ligt KM**, Korevaar J, **Siesling S**. Primary Secondary Cancer Care Registry (PSCCR): following breast cancer patients from their first complaints up to 15 year after diagnosis. Bossche Mamma Congres; 12-13 juni 2018; St. Michielgestel.

## 2.4 Presentaties en abstracts

Granzier R, van Nijnatten T, Engelen S, **de Munck L**, **Siesling S**, Smidt M. Neo-adjuvant chemotherapy in mucinous breast cancer: is it of clinical added value? EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

Heeg E, **Schreuder K**, Spronk PE, Oosterwijk JC, **Siesling S**, Vrancken-Peeters MT. Beweging van borstkanker patiënten tussen verschillende ziekenhuizen in Nederland: een studie naar de omvang en impact op de tijd tot behandeling. Chirurgicaldagen; 24-25 mei 2018; Veldhoven.

Heeg E, Spronk PE, Bijker N, Jager A, Mureau MA, **Verloop J**, **Siesling S**, Vrancken Peeters MT. Improving the quality of breast cancer care by a nation-wide audit: 5-year results of the NABON breast cancer audit. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

Heeg E, **Schreuder K**, Spronk PE, Oosterwijk JC, **Siesling S**, Vrancken Peeters MT. The impact of patient shifts between hospitals on breast cancer care: a population based study in the Netherlands. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

Heins M, **Verloop J**, **de Ligt KM**, **Siesling S**, Korevaar JC. Long-term effects of different breast cancer treatment. Ca-PRI, The Cancer and Primary Care Research International Network; 18-20 april 2018; Groningen.

**Hendriks M**, **van Vegchel T**, **Ebben K**, **Siesling S**, **Verbeek X**. Clinical practice guidelines in the era of data driven personalized cancer treatment: representing recommendations of the Dutch breast cancer guideline into clinical decision trees focused on implementation and collaborative learning. NCCN Annual Conference; 22-24 maart 2018; Orlando.

Hoedjes M, **Mols F**, de Kruijff A, de Boer MR, Buffart L, **Beijer S**, **Horevoorts NJ**, **Ezendam NP**, Kampman E, Seidell JC. Optimal timing and method for promoting adherence to lifestyle recommendations in postmenopausal breast cancer survivors. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

Kramer I, Schaapveld M, Oldenburg HS, Sonke GS, McCool D, van Leeuwen FE, van de Vijver KK, Russell NS, Linn SC, **Siesling S**, van Oordt CW, Schmidt MK. The influence of various adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

Meurs CJ, van Rosmalen J, Menke-Pluijmers MB, **de Munck L**, **Siesling S**, Westenend PJ. Underestimation of invasive breast cancer in 2,892 biopsies with ductal carcinoma in situ: a prediction model and characteristics of 589 invasive cancers. BDIAP Meeting, British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland; 19-22 juni 2018; Maastricht.

Overbeek JA, van Herk-Sukel MP, **Vissers PA**, van der Heijden AA, Bronsveld HK, Herings RM, Schmidt MK, Nijpels G. Severity of breast cancer associated with type 2 diabetes and not with insulin treatment. ISPOR Conference; 10-14 november 2018; Barcelona.

Rombouts AJ, Huising J, Hugen N, **Siesling S**, de Wilt H, Poortmans PM, Nagtegaal I. Radiation therapy associated sarcoma after breast cancer treatment: a population-based study. SSO, Society Surgical Oncology Symposium; 21-24 maart 2018; Chicago, Illinois.

Samiei S, van Nijnatten T, **de Munck L**, Keymeulen K, Simons J, Kooreman L, **Siesling S**, Lobbes M, Smidt M. Positive association between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**Schreuder K**, Kuijer A, Bentum S, van Dalen T, **Siesling S**. Use and impact of the 21-gene recurrence score in relation to the clinical risk of developing metastases in early breast cancer patients in the Netherlands. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**Siesling S, Verloop J**, Heins M, **de Ligt KM**, Korevaar J. Primary and secondary cancer care registry: long term effects. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

**Siesling S**, Abbas S, van der Palen J, van der Valk P, Heuvelmans M, Heijmans H, Jobsen J, Struikmans H. Pulmonary complications in breast cancer survivors: long-term effects of adjuvant treatment? EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**Siesling S, van Steenbeek C, van Maaren MC, Witteveen A**, Mentink R, Pleihuis R, **Verbeek X**, Koffijberg E. Validation of prediction models: a comparison of manual and semi-automated validation using cancer registry data. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

**Siesling S, van Maaren MC, Verhoeven RH**, Kneepkens R, Verbaan J, **Huijgens PC, Lemmens VE**. When will breast cancer patients be cured?: a model predicting conditional extra risk on mortality. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

**Smits T, Schreuder K**, Tsuruda K, **Siesling S**, Nygard J. Comparison of quality indicators concerning breast cancer care on a national and hospital level. ENCR, European Network of Cancer Registries Scientific Meeting and General Assembly; 26-28 september 2018; Kopenhagen.

Traa F, van Kuijk S, Vane M, Engelen S, van Kaathoven B, **Siesling S, van Maaren MC**, Moosdorff M, Smidt M. Staging in estrogen receptor positive breast tumors: pathological staging versus bioscore. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**van Maaren MC**, le Cessie S, Strobbe LJ, Groothuis-Oudshoorn CG, Poortmans PM, **Siesling S**. A comparison of different statistical techniques dealing with confounding: measuring the effect of breast-conserving therapy and mastectomy on survival. WEON Congres, Werkgroep Epidemiologisch Onderzoek Nederland; 7-8 juni 2018; Bilthoven.

**van Maaren MC**, Strobbe JA, Poortmans PM, **Siesling S**. Ten-year conditional recurrence risk and survival according to prognostic subgroups in breast cancer patients and survivors in the Netherlands. WEON Congres, Werkgroep Epidemiologisch Onderzoek Nederland; 7-8 juni 2018; Bilthoven.

**van Maaren MC**, Strobbe LJ, Koppert LB, Poortmans PM, **Siesling S**. Time trends and regional variation in breast-conserving treatment in the Netherlands: a nationwide population-based study. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

**van Maaren MC, Verhoeven RH**, Kneepkens RF, Verbaan JJ, **Huijgens PC, Lemmens VE, Siesling S**. When will a breast cancer patient be cured?: a prediction model predicting the conditional extra risk on mortality. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

van Steenhoven JE, Kuijer A, van Bommel AC, Elias S, Smorenburg C, Rutgers E, **Siesling S**, van Dalen T. Impact of the 70-gene signature on chemotherapy administration in Dutch early stage breast cancer patients. SSO, Society Surgical Oncology Symposium; 21-24 maart 2018; Chicago, Illinois.

---

van Uden D, **van Maaren MC**, Strobbe L, Bult P, Koos VD, **Siesling S**, Hans DW, Blanken-Peeters C. Breast cancer subtypes in stage IV inflammatory breast cancer and the effect of resection of the primary tumor on survival. ESSO, The European Society of Surgical Oncology Congress; 10-12 oktober 2018; Boedapest.

van Uden D, **van Maaren MC**, Bult P, Strobbe L, **Siesling S**, de Wilt H, Blanken-Peeters C. Molecular subtypes in inflammatory breast cancer: a descriptive analysis using the Netherlands cancer registry. EBCC, European Breast Cancer Conference; 21-23 maart 2018; Barcelona.

## 3 Bot-en wekedelentumoren

### 3.1 Publicaties met impactfactor

Stiller CA, Botta L, Brewster DH, **Ho VK**, Frezza AM, Whelan J, Casali PG, Trama A, Gatta G; EUROCARE-5 Working Group. Survival of adults with cancers of bone or soft tissue in Europe-Report from the EUROCARE-5 study. *Cancer Epidemiol.* 2018 Aug 31;56:146-153. doi: 10.1016/j.canep.2018.08.010. [Epub ahead of print]  
Impactfactor: 2,888

Timbergen MJ, **van de Poll-Franse LV**, Grünhagen DJ, van der Graaf WT, Sleijfer S, Verhoef C, Husson O. Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study. *Qual Life Res.* 2018 Jul 16. doi: 10.1007/s11136-018-1931-3. [Epub ahead of print]  
Impactfactor: 2,392

van Praag VM, Rueten-Budde AJ, **Ho VK**, Dijkstra PD; Study group Bone and Soft tissue tumours (WeBot), Fiocco M, van de Sande MA. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. *Surg Oncol.* 2018 Sep;27(3):402-408. doi: 10.1016/j.suronc.2018.05.009. Epub 2018 May 6.  
Impactfactor: 2,558

Vos M, **Ho VK**, Oosten AW, Verhoef C, Sleijfer S. Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study. *Oncologist.* 2018 Sep 6. pii: theoncologist.2017-0383. doi: 10.1634/theoncologist.2017-0383. [Epub ahead of print]  
Impactfactor: 5,306

## 4 Darmkanker

### 4.1 Publicaties met impactfactor

Baas J, Krens L, Bohringer S, **Mol L**, Punt C, Guchelaar HJ, Gelderblom H. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. PLoS One. 2018 Dec 17;13(12):e0208080. doi: 10.1371/journal.pone.0208080. eCollection 2018. Impactfactor: 2,766

Breugom AJ, Bastiaannet E, Boelens PG, Van Eycken E, Iversen LH, Martling A, Johansson R, Evans T, Lawton S, O'Brien KM, Ortiz H, Janciauskiene R, Dekkers OM, Rutten HJ, Liefers GJ, **Lemmens VE**, van de Velde CJ. Oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer - A EURECCA international comparison between the Netherlands, Belgium, Denmark, Sweden, England, Ireland, Spain, and Lithuania. Eur J Surg Oncol. 2018 May 26. pii: S0748-7983(18)31079-5. doi: 10.1016/j.ejso.2018.05.025. [Epub ahead of print] Impactfactor: 3,688

Brouwer NP, **Bos AC**, **Lemmens VE**, Tanis PJ, Hugten N, Nagtegaal ID, de Wilt JH, **Verhoeven RH**. An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int J Cancer. 2018 Aug 10. doi: 10.1002/ijc.31785. [Epub ahead of print] Impactfactor: 7,36

Brouwer NP, Stijns RC, **Lemmens VE**, Nagtegaal ID, Beets-Tan RG, Fütterer JJ, Tanis PJ, **Verhoeven RH**, de Wilt JH. Clinical lymph node staging in colorectal cancer; a flip of the coin? Eur J Surg Oncol. 2018 Apr 17. pii: S0748-7983(18)31013-8. doi: 10.1016/j.ejso.2018.04.008. [Epub ahead of print] Impactfactor: 3,688

de Neree Tot Babberich MP, Detering R, Dekker JW, **Elferink MA**, Tollenaar RA, Wouters MW, Tanis PJ; Dutch ColoRectal Audit Group (**Lemmens VE**). Achievements in colorectal cancer care during 8 years of auditing in The Netherlands. Eur J Surg Oncol. 2018 Jun 8. pii: S0748-7983(18)31117-X. doi: 10.1016/j.ejso.2018.06.001. [Epub ahead of print] Impactfactor: 3,688

Hagemans JA, Alberda WJ, Verstegen M, de Wilt JH, Verhoef C, **Elferink MA**, Burger JW. Hospital volume and outcome in rectal cancer patients; results of a population-based study in the Netherlands. Eur J Surg Oncol. 2018 Dec 26. pii: S0748-7983(18)32040-7. doi: 10.1016/j.ejso. 2018.12.018. [Epub ahead of print] Impactfactor: 3,688

Koëter T, Bonhof CS, Schoormans D, Martijnse IS, Langenhoff BS, Zimmerman DD, **Mols F**, Wasowicz DK. Long-term Outcomes After Surgery Involving the Pelvic Floor in Rectal Cancer: Physical Activity, Quality of Life, and Health Status. J Gastrointest Surg. 2018 Oct 29. doi: 10.1007/s11605-018-4014-4. [Epub ahead of print] Impactfactor: 2,813

**Legué LM**, Creemers GJ, de Hingh IH, **Lemmens VE**, Huysentruyt CJ. Review: Pathology and Its Clinical Relevance of Mucinous Appendiceal Neoplasms and Pseudomyxoma Peritonei. Clin Colorectal Cancer. 2018 Dec 6. pii: S1533-0028(18)30467-5. doi: 10.1016/j.clcc.2018.11.007. [Epub ahead of print] Review. Impactfactor: 3,861

**Mols F**, Schoormans D, **de Hingh IH**, **Oerlemans S**, Husson O. Symptoms of anxiety and depression among colorectal cancer survivors from the population-based, longitudinal PROFILES Registry: Prevalence, predictors, and impact on quality of life. Cancer. 2018 Apr 6. doi: 10.1002/cncr.31369. [Epub ahead of print] Impactfactor: 6,537



Montroni I, Ugolini G, Saur NM, Spinelli A, Rostoft S, Millan M, Wolthuis A, Daniels IR, Hompes R, Penna M, Fürst A, Papamichael D, Desai AM, Cascinu S, Gérard JP, Myint AS, **Lemmens VE**, Berho M, Lawler M, De Liguori Carino N, Potenti F, Nanni O, Altini M, Beets G, Rutten H, Winchester D, Wexner SD, Audisio RA. Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. *Eur J Surg Oncol*. 2018 Aug 15. pii: S0748-7983(18)31272-1. doi: 10.1016/j.ejso.2018.08.003. [Epub ahead of print] Review. Impactfactor: 3,688

Oliai Araghi S, Kieffe-de Jong JC, Dijk SC, Swart KM, van Laarhoven HW, Schoor NM, de Groot LC, **Lemmens VE**, Stricker BH, Uitterlinden AG, Velde NV. Folic acid and vitamin-B12 supplementation and the risk of cancer: long-term follow-up of the B-vitamins for the Prevention Of Osteoporotic Fractures (B-PROOF) trial. *Cancer Epidemiol Biomarkers Prev*. 2018 Oct 19. pii: cebp.1198.2018. doi: 10.1158/1055-9965.EPI-17-1198. [Epub ahead of print] Impactfactor: 4,554

Rombouts AJ, Hugen N, **Verhoeven RH**, **Elferink MA**, Poortmans PM, Nagtegaal ID, de Wilt JH. Tumor response after long interval comparing 5x5Gy radiation therapy with chemoradiation therapy in rectal cancer patients. *Eur J Surg Oncol*. 2018 Mar 27. pii: S0748-7983(18)30986-7. doi: 10.1016/j.ejso.2018.03.017. [Epub ahead of print] Impactfactor: 3,688

van Baar H, **Beijer S**, Bours MJ, Weijenberg MP, van Zutphen M, van Duijnhoven FJ, Slooter GD, Pruijt JF, Dronkers JJ, Haringhuizen A, Spillenaar Bilgen EJ, Hansson BM, de Wilt JH, Kampman E, Winkels RM. Low radiographic muscle density is associated with lower overall and disease-free survival in early-stage colorectal cancer patients. *J Cancer Res Clin Oncol*. 2018 Aug 17. doi: 10.1007/s00432-018-2736-z. [Epub ahead of print] Impactfactor: 3,282

van der Vlugt M, Grobbee EJ, Bossuyt PM, **Bos AC**, Kuipers EJ, Lansdorp-Vogelaar I, Spaander MC, Dekker E. Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program. *Clin Gastroenterol Hepatol*. 2018 Feb 7. pii: S1542-3565(18)30107-1. doi: 10.1016/j.cgh.2018.01.037. [Epub ahead of print] Impactfactor: 7,680

#### 4.2 Overige publicaties

**Elferink MA**, Toes-Zoutendijk E, **Vink GR**, Lansdorp-Vogelaar I, Meijer GA, Dekker E, **Lemmens VE**. Landelijk bevolkingsonderzoek naar colorectaal carcinoom: resultaten van de eerste jaren sinds de invoering in 2014. *Ned Tijdsch Geneesk* 2018 Maart 3:162(9);11-15.

#### 4.3 Proefschriften en promoties

**Bos AC**. Real-world aspects of colorectal cancer survival in the Netherlands. Rotterdam: Erasmus Universiteit; 16 mei 2018. Promotoren: **VE Lemmens**, **PC Huijgens**. Overige leden: M Koopman, C Verhoef JH de Wilt. Co-promotor: **FN van Erning**.

#### 4.4 Posters

**Geleijnse G**, **Aklecha H**, **Vroling M**, **Verhoeven RH**, **van Erning FN**, **Vissers PA**, Buijs JC, **Verbeek XA**. Using process mining to evaluate colon cancer guideline adherence with cancer registry data: a case study. *AMIA Annual Symposium*; 3-7 november 2018: San Francisco.

#### 4.5 Presentaties en abstracts

Brouwer NP, **van Erning FN**, Bastiaannet E, Dekker J, Rutten H, de Wilt H. The magnitude of postoperative mortality after colorectal cancer: surgery in elderly patients revised. *SSO, Society Surgical Oncology Symposium*; 21-24 maart 2018; Chicago, Illinois.



Hoedjes M, de Kruif A, **Mols F**, Bours M, **Beijer S**, Winkels R, Westerman M, Seidell JC, Kampman E. Exploration of needs and preferences for dietary support in colorectal cancer survivors: a mixed-methods study. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

Kuiper JG, van Herk-Sukel MP, **Lemmens VE**, Herings RC. Insight into the role of the general practitioner in the management of colorectal cancer: record linkage of the Netherlands Cancer Registry and the general practitioner database of the PHARMO Database Network. International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 22-26 augustus 2018; Praag.

Kuiper JG, van Herk-Sukel MP, **Lemmens VE**, Herings RC. Use of antipsychotics and the risk of colorectal cancer: a case-control study using data from the linked Netherlands Cancer Registry and PHARMO Database Network population. International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 22-26 augustus 2018; Praag.

Révész D, van Kuijk SM, **Mols F**, van Duijnhoven FJ, Winkels RM, Hoofs H, Kant IJ, Smits LJ, **van de Poll-Franse LV**, Kampman E, **Beijer S**, Weijenberg MP, Bours MJ. Development and validation of clinical prediction models for quality of life in colorectal cancer survivors. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

Rombouts AJ, **Elferink MA**, Hugén N, Poortmans PM, Nagtegaal ID, de Wilt JH. A second primary rectal cancer following pelvic radiation therapy: a population based study . ESCP Meeting, European Society of ColoProctology; 26-28 september 2018; Nice.

Rombouts AJ, Hugén N, **Verhoeven RH**, Kuiper JG, Poortmans PM, de Wilt JH, Nagtegaal ID. Is tumour response to preoperative therapy among rectal cancer patients influenced by angiotensin-converting enzyme inhibitors or angiotensin receptor blockade? ESCP Meeting, European Society of ColoProctology; 26-28 september 2018; Nice.

**van Veen M**, **Mols F**, Bours M, Weijenberg M, Kampman E, **Beijer S**. Adherence to the WCRF/AICR recommendations for cancer prevention is associated with better health-related quality of life among colorectal cancer survivors. MASCC/ISOO annual meeting; 28-30 juni 2018; Wenen.

**van Veen MR**, **Mols F**, Bours M, Winkels R, Weijenberg M, Kampman E, **Beijer S**. Associations between the WCRF/AICR recommendations and quality of life and fatigue among colorectal cancer survivors. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

Verseveld M, de Wilt J, **Elferink MA**, de Graaf E, Verhoef C, Pouwels S, Doornebosch P. Local excision for rectal cancer: a population-based overview of clinical practice and outcome. ESCP Meeting, European Society of ColoProctology; 26-28 september 2018; Nice.

## 5 Gynaecologische tumoren

### 5.1 Publicaties met impactfactor

**Bonhof CS, Mols F**, Vos MC, Pijnenborg JM, Boll D, Vreugdenhil G, **Ezendam NP, van de Poll-Franse LV**. Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study. *Gynecol Oncol*. 2018 Mar 28. pii: S0090-8258(18)30232-4. doi: 10.1016/j.ygyno.2018.03.052. [Epub ahead of print]  
Impactfactor: 4,540

Camara C, Caroline Vos M, **de Rooij BH**, Pijnenborg JM, Boll D, **van de Poll-Franse LV, Ezendam NP**. The role of positive psychological changes in anxiety and depression of patients with ovarian tumors and their partners: an observational study from the population-based PROFILES registry. *Support Care Cancer*. 2018 Jun 29. doi: 10.1007/s00520-018-4327-6. [Epub ahead of print]  
Impactfactor: 2,676

de Boer SM, Powell ME, Mileshekin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LC, Smit VT, Singh N, Do V, D'Amico R, Nout RA, Feeney A, **Verhoeven-Adema KW**, Putter H, Creutzberg CL; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: *Lancet Oncol*. 2018 Apr;19(4):e184.  
Impactfactor: 36,421

de Groot JJ, **Timmermans M**, Maessen JM, Winkens B, Dirksen CD, Slangen BF, van der Weijden T. Quality improvement strategies for organizational change: a multiphase observational study to increase insight into nonparticipating organizations. *BMC Health Serv Res*. 2018 Dec 29;18(1):1011. doi: 10.1186/s12913-018-3847-6.  
Impactfactor: 1,843

**de Rooij BH, Ezendam NP**, Vos MC, Pijnenborg JM, Boll D, Kruitwagen RF, **van de Poll-Franse LV**. Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: New insights for tailored delivery. *Cancer*. 2018 Nov 30. doi: 10.1002/cncr.31844. [Epub ahead of print]  
Impactfactor: 6,537

**de Rooij BH**, Ikiz H, Boll D, Pijnenborg JM, Pijlman BM, Kruitwagen RF, **van de Poll-Franse LV**, Vos MC, **Ezendam NP**. Recurrent Cancer Is Associated With Dissatisfaction With Care-A Longitudinal Analysis Among Ovarian and Endometrial Cancer Patients. *Int J Gynecol Cancer*. 2018 Mar;28(3):614-622. doi: 10.1097/IGC.0000000000001204.  
Impactfactor: 2,192

**de Rooij BH**, Thomas TH, Post KE, Flanagan J, **Ezendam NP**, Peppercorn J, Dizon DS. Survivorship care planning in gynecologic oncology-perspectives from patients, caregivers, and health care providers. *J Cancer Surviv*. 2018 Sep 12. doi: 10.1007/s11764-018-0713-9. [Epub ahead of print]  
Impactfactor: 3,713

**de Rooij BH, Ezendam NP, Nicolaije KA**, Lodder P, Vos MC, Pijnenborg JM, Boll D, Kruitwagen RF, **van de Poll-Franse LV**. Survivorship care plans have a negative impact on long-term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. *Qual Life Res*. 2018 Mar 6. doi: 10.1007/s11136-018-1825-4. [Epub ahead of print]  
Impactfactor: 2,392

Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, **Aben KK**, Anton-Culver H, Antonenkova N, Bandera EV, Bean YT, Beckmann MW, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall CK, Høgdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Jung AY, Karlan BY, Kellar M, Kiemeny LA, Kiong Lim B, Kjaer SK, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lele S, Lester J, Levine DA, Li Z, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Odunsi K, Olson SH, Orlov I, Orsulic S, Paul J, Pejovic T, Peltari LM, Permuth JB, Pike MC, Poole EM, Rosen B, Rossing MA, Rothstein JH, Runnebaum IB, Rzepecka IK, Schernhammer E, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Thomsen L, Tworoger SS, van Altena AM, Vergote I, Vestheim Thomsen LC, Vierkant RA, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu AH, Wu X, Xiang YB, Yang H, Zheng W, Ziogas A, Lee AW, Pearce CL, Berchuck A, Schildkraut JM, Ramus SJ, Monteiro AN, Narod SA, Sellers TA, Gayther SA, Kelemen LE, Chenevix-Trench G, Risch HA, Pharoah PD, Goode EL, Phelan CM. **Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.** PLoS One. 2018 Jul 6;13(7): e0197561. doi: 10.1371/journal.pone.0197561. eCollection 2018. Impactfactor: 2,766

**Ezendam NP, de Rooij BH**, Kruitwagen RF, Creutzberg CL, van Loon I, Boll D, Vos MC, **van de Poll-Franse LV**. Endometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial. *Trials*. 2018 Apr 16;19(1):227. doi: 10.1186/s13063-018-2611-x. Impactfactor: 2,067

Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Peltari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, Lu K, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlov I, Vestheim Thomsen LC, Bjorge L, Krakstad C, Tangen IL, Kiemeny LA, **Aben KK**, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubiński J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A; Ovarian Cancer Association Consortium. **rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.** *Int J Mol Sci*. 2018 Aug 21;19(9). pii: E2473. doi: 10.3390/ijms19092473. Impactfactor: 3,687

Pleunis N, Leermakers ME, van der Wurff AA, Klinkhamer PJ, **Ezendam NP**, Boll D, de Hullu JA, Pijnenborg JM. **Surgical margins in squamous cell carcinoma, different for the vulva?** *Eur J Surg Oncol*. 2018 Oct;44(10):1555-1561. doi: 10.1016/j.ejso.2018.05.031. Epub 2018 Jun 6. Impactfactor: 3,688

Rietveld MJ, Husson O, Vos MC, **van de Poll-Franse LV**, Ottevanger PB, **Ezendam NP**. Association between information provision and supportive care needs among ovarian cancer survivors: A cross-sectional study from the PROFILES registry. *Psychooncology*. 2018 Apr 23. doi: 10.1002/pon.4742. [Epub ahead of print] Impactfactor: 3,455

Rietveld MJ, Husson O, Vos MC, **van de Poll-Franse LV**, Ottevanger PB, **Ezendam NP**. Presence of gastro-intestinal symptoms in ovarian cancer patients during survivorship: a cross-sectional study from the PROFILES registry. *Support Care Cancer*. 2018 Oct 17. doi: 10.1007/s00520-018-4510-9. [Epub ahead of print]  
Impactfactor: 2,676

**Schuurman MS**, Kruitwagen RF, Portielje JE, Roes EM, **Lemmens VE**, **van der Aa MA**. Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis. *Gynecol Oncol*. 2018 Mar 4. pii: S0090-8258(18)30136-7. doi: 10.1016/j.ygyno.2018.02.017. [Epub ahead of print]  
Impactfactor: 4,540

Thong MS, **Mols F**, Kaptein AA, Boll D, Vos C, Pijnenborg JM, **van de Poll-Franse LV**, **Ezendam NP**. Illness perceptions are associated with higher health care use in survivors of endometrial cancer-a study from the population-based PROFILES registry. *Support Care Cancer*. 2018 Sep 13. doi: 10.1007/s00520-018-4451-3. [Epub ahead of print]  
Impactfactor: 2,676

**Timmermans M**, **van der Aa MA**, Lalisang RI, Witteveen PO, Van de Vijver KK, Kruitwagen RF, Sonke GS. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. *Gynecol Oncol*. 2018 Jul 9. pii: S0090-8258(18)31017-5. doi: 10.1016/j.ygyno.2018.07.004. [Epub ahead of print]  
Impactfactor: 4,540

**Timmermans M**, Sonke GS, van Driel WJ, Lalisang RI, Ottevanger PB, de Kroon CD, Van de Vijver KK, **van der Aa MA**, Kruitwagen RF. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands. *Eur J Obstet Gynecol Reprod Biol*. 2018 Mar 6;223:98-102. doi: 10.1016/j.ejogrb.2018.02.029. [Epub ahead of print]  
Impactfactor: 1,809

van der Linden M, **Schuurman MS**, Bulten J, Massuger LF, Int'Hout J, **van der Aa MA**, de Hullu JA. Stop routine screening for associated malignancies in cutaneous non-invasive vulvar Paget disease? *Br J Dermatol*. 2018 Jun 19. doi: 10.1111/bjd.16894. [Epub ahead of print]  
Impactfactor: 6,129

Wortman BG, Bosse T, Nout RA, Lutgens LC, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KA, **Verhoeven-Adema KW**, Smit VT, Creutzberg CL; PORTEC Study Group. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. *Gynecol Oncol*. 2018 Oct;151(1):69-75. doi: 10.1016/j.ygyno.2018.07.020. Epub 2018 Aug 3.  
Impactfactor: 4,540

## 5.2 Overige publicaties

Versluis MA, Pielsticker C, **van der Aa MA**, de Bruyn M, Hollema H, Nijman HW. Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. *Oncology*. 2018 May 23:1-9. doi: 10.1159/000488531. [Epub ahead of print]

Wollinga T, **Ezendam NP**, Eggink FA, Smink M, van Hamont D, Pijlman B, Boss E, Robbe EJ, Ngo H, Boll D, Mom CH, **van der Aa MA**, Kruitwagen RF, Nijman HW, Pijnenborg JM. Implementation of laparoscopic hysterectomy for endometrial cancer over the past decade. *Gynecol Surg*. 2018;15(1):7. doi: 10.1186/s10397-018-1040-x. Epub 2018 Feb 27.

## 5.3 Proefschriften en promoties

**de Rooij BH**. Survivorship care planning for women with a gynecological cancer: does information heal or hurt? Tilburg: Universiteit Tilburg; 20 december 2018. Promotor: **LV van de Poll-Franse**. Co-promotor: **NP Ezendam**. Overige leden: CL Creutzberg, AA Kaptein, EJ Krahmer, **S Siesling**, LR van Lonkhuijzen, **F Mols**.

## 5.4 Posters

Blömer N, Wenzel H, van Manen J, Riemersma S, **Siesling S, van der Aa MA**. Screening history of women 60 years and older diagnosed with cervical cancer in the Netherlands. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

**de Rooij BH**, Hagan T, Post KE, Flanagan JM, Peppercorn JM, Dizon DS. Survivorship care planning in gynecologic oncology: perspectives from patients, caregivers and health care providers. Cancer Survivorship Symposium; 16-17 februari 2018; Orlando.

**Timmermans M**, Sonke GS, van de Vijver KK, Ottevanger PB, Nijman HW, **van der Aa MA**, Kruitwagen RF. Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer: results from a population-based study. IGCS, International Gynecologic Cancer Society Meeting; 14-16 september 2018; Kyoto.

**Timmermans M**, Zwakman N, Sonke GS, van de Vijver KK, Duk MJ, **van der Aa MA**, Kruitwagen RF. Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer. IGCS, International Gynecologic Cancer Society Meeting; 14-16 september 2018; Kyoto.

## 5.5 Presentaties en abstracts

**Blomer N**, Wenzel H, **van Manen J**, Riemersma S, **Siesling S, van der Aa MA**. Screening history of women 60 years and older diagnosed with cervical cancer in the Netherlands. IACR, International Association of Cancer Registries Conference; 13-15 november 2018; Arequipa.

Burg L, **Timmermans M, van der Aa MA**, Boll D, Rovers K, de Hingh I, van Altena A. Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands. IGCS Meeting, International Gynecologic Cancer Society; 14-16 september 2018; Kyoto.

Burg L, **Timmermans M, van der Aa MA**, Boll D, Rovers K, de Hingh I, van Altena A. Trends in treatment and survival of peritoneal metastases of gynecological origin: a population-based study in the Netherlands. IGCS Meeting, International Gynecologic Cancer Society; 14-16 september 2018; Kyoto.

**de Rooij BH, Ezendam NP**, Nicolaije KA, Vos MC, Pijnenborg JM, Boll D, Kruitwagen RF, **van de Poll-Franse LV**. The indirect effects of Survivorship Care Plans on quality of life, anxiety and depression - the ROGY Care trial. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

van Baal J, van de Vijver K, **van der Aa MA**, Sonke G, van Driel W, Kenter G, Amant F, Lok C. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. IGCS Meeting, International Gynecologic Cancer Society; 14-16 september 2018; Kyoto.

## 6 Hemato-oncologie

### 6.1 Publicaties met impactfactor

**Arts LP, Oerlemans S**, Tick L, Koster A, Roerdink HT, **van de Poll-Franse LV**. More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: Results from the population-based PROFILES registry. *Cancer*. 2018 Apr 26. doi: 10.1002/cncr.31410. [Epub ahead of print]  
Impactfactor: 6,537

Dara A, Mook BB, Doorduijn JK, van den Bent MJ, **Dinmohamed AG**, Bromberg JE. Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis. *J Neurooncol*. 2018 Apr 9. doi: 10.1007/s11060-018-2849-x. [Epub ahead of print]  
Impactfactor: 3,060

**Dinmohamed AG**, Posthuma EF, **Visser O**, Kater AP, Raymakers RA, Doorduijn JK. Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in the Netherlands. *Blood*. 2018 Jan 30. pii: blood-2017-12-820381. doi: 10.1182/blood-2017-12-820381. [Epub ahead of print] No abstract available.  
Impactfactor: 15,132

Geelen IG, Sandin F, Thielen N, Janssen JJ, Hoogendoorn M, **Visser O**, Cornelissen JJ, Hoglund M, Westerweel PE. Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients. *Leukemia*. 2018 Apr 19. doi: 10.1038/s41375-018-0136-7. [Epub ahead of print] No abstract available.  
Impactfactor: 10,023

Husson O, **Huijgens PC**, van der Graaf WT. Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies. *Blood*. 2018 Jun 12. pii: blood-2017-11-778555. doi: 10.1182/blood-2017-11-778555. [Epub ahead of print]  
Impactfactor: 15,132

Kalin B, Pijnappel EN, van Gelder M, **Visser O**, van de Loosdrecht AA, Ossenkoppele GJ, Cornelissen JJ, **Dinmohamed AG**, Jongen-Lavrencic M. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. *Cancer Epidemiol*. 2018 Oct 19;57:90-96. doi: 10.1016/j.canep.2018.09.007. [Epub ahead of print]  
Impactfactor: 2,888

Reedijk AM, Klein K, Coebergh JW, Kremer LC, **Dinmohamed AG**, de Haas V, Versluijs AB, Ossenkoppele GJ, Beverloo HB, Pieters R, Zwaan CM, Kaspers GJ, Karim-Kos HE. Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. *Leukemia*. 2018 Dec 19. doi: 10.1038/s41375-018-0314-7. [Epub ahead of print]  
Impactfactor: 10,023

Rigter LS, Schaapveld M, Janus CP, Krol AD, van der Maazen RW, Roesink J, Zijlstra JM, van Imhoff GW, Poortmans PM, Beijert M, Lugtenburg PJ, **Visser O**, Snaebjornsson P, van Eggermond AM, Aleman BM, van Leeuwen FE, van Leerdam ME. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer. *Cancer Med*. 2018 Dec 27. doi: 10.1002/cam4.1922. [Epub ahead of print]  
Impactfactor: 3,202

Thielen FW, **Blommestein HM**, Oosten LEM, Calkoen FG, Lankester AC, Zwaginga JJ, Le Blanc K, Redondo A, Sánchez-Guijo F, Algeri M, Locatelli F, Fibbe WE, Uyl-de Groot CA. Second-Line Treatment for Acute Graft-Versus-Host Disease with Mesenchymal Stromal Cells: A decision model. *Eur J Haematol*. 2018 Aug 6. doi: 10.1111/ejh.13158. [Epub ahead of print]  
Impactfactor: 2,595



van der Straten L, **Dinmohamed AG**, Westerweel PE, Langerak AW, Riedl J, Doorduijn JK, Kater AP, Levin MD. Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. *Leuk Lymphoma*. 2018 Apr 4:1-5. doi: 10.1080/10428194.2018.1452215. [Epub ahead of print] No abstract available. Impactfactor: 2,644

van Roeden SE, van Houwelingen F, Donkers CM, **Hogewoning SJ**, de Lange MM, van der Hoek W, Kampschreur LM, Bonten MJ, Hoepelman AI, Bleeker-Rovers CP, Wever PC, Oosterheert JJ. Exposure to *Coxiella burnetii* and risk of non-Hodgkin lymphoma: a retrospective population-based analysis in the Netherlands. *Lancet Haematol*. 2018 Apr 9. pii: S2352-3026(18)30038-3. doi: 10.1016/S2352-3026(18)30038-3. [Epub ahead of print] Impactfactor: 10,698

van Tienen C, **Visser O**, Lugtenburg P, Taylor G, Cook L. Overrepresentation of patients from HTLV-1 endemic countries among T cell Non-Hodgkin lymphomas in the Netherlands: an indication of under-diagnosis of Adult T cell leukaemia/lymphoma. *Br J Haematol*. 2018 Mar 12. doi: 10.1111/bjh.15160. [Epub ahead of print] No abstract available. Impactfactor: 5,128

## 6.2 Overige publicaties

**Dinmohamed AG, Visser O**, Doorduijn JK, Lugtenburg PJ. Treatment and survival of patients with primary effusion lymphoma in the Netherlands: a population-based analysis, 2002-2015. *HemaSphere*: October 2018 - Volume 2 - Issue 5 - p e143 doi: 10.1097/HS9.000000000000143.

## 6.3 Proefschriften en promoties

van der Poel MW. Diffuse large B-cell lymphoma and multiple myeloma in elderly patients: treatment-decision making and health-related quality of life. Maastricht: Universiteit Maastricht; 25 mei 2018. Promotoren: H. Schouten, **LV van de Poll-Franse**.

## 6.4 Posters

**Arts LP, Oerlemans S**, Tick L, Koster A, Roerdink HT, **van de poll-Franse LV**. Psychological distress is associated with increased health care use among lymphoma and CLL survivors: results from the population-based PROFILES-registry. *ECRS, European Cancer Rehabilitation & Survivorship Symposium*; 10-11 september 2018; Kopenhagen.

**Brink M**, Minnema MC, **Visser O**, Broijl A, van de Donk NW, Sonneveld P, Zweegman S, **Dinmohamed AG**. Impact of prior malignancies on the development of subsequent malignancies and survival in multiple myeloma: a nationwide population-based study in the Netherlands. *EHA, European Hematology Association Congress*; 14-17 juni 2018; Stockholm.

**Brink M, Visser O**, Zweegman S, Sonneveld P, Broijl A, van de Donk NW, **Dinmohamed AG**. Treatment and survival of patients with primary plasma cell leukemia: a nationwide population-based study among 179 patients diagnosed in the Netherlands from 1989 to 2015. *DHC, Dutch Hematology Congress*; 24-26 januari 2018; Arnhem.

**Brink M, Visser O**, Zweegman S, Sonneveld P, Broijl A, van de Donk NW, **Dinmohamed AG**. Treatment and survival of patients with primary plasma cell leukemia: a nationwide population-based study among 179 patients diagnosed in the Netherlands from 1989 to 2015. *EHA, European Hematology Association Congress*; 14-17 juni 2018; Stockholm.

**Dinmohamed A, Damhuis RA, Visser O**, Janssen J, Huls G, van de Losodrecht A. Weekend versus weekday diagnosis and early mortality in acute promyelocytic leukemia: a population-based analysis in the Netherlands. *EHA, European Hematology Association Congress*; 14-17 juni 2018; Stockholm.

Slot S, **Visser O**, Schaap M, Janssen J, te Broekhorst P, Zweegman S, **Dinmohamed AG**. Primary therapy and survival in primary myelofibrosis: a nationwide population-based analysis among 1,445 patients diagnosed in the Netherlands between 2001 and 2015. *EHA, European Hematology Association Congress*; 14-17 juni 2018; Stockholm.

**van der Straten L**, Levin MD, **Visser O**, Blijlevens NM, Cornelissen JJ, Doorduijn JK, Kater AP, **Dinmohamed AG**. Effectiveness of ibrutinib for the treatment of chronic lymphocytic leukemia in daily practice in the Netherlands: a nationwide population-based cohort study. EHA, European Hematology Association Congres; 14-17 juni 2018; Stockholm.

**van der Straten L**, Levin MD, **Visser O**, Posthuma EF, Doorduijn JK, Kater AP, **Dinmohamed AG**. Prognostic and first-line treatment in chronic lymphocytic leukemia: a contemporary, nationwide, population-based analysis among 1,677 patients diagnosed in the Netherlands. EHA, European Hematology Association Congres; 14-17 juni 2018; Stockholm.

**van der Straten L**, Levin MD, **Visser O**, Posthuma EF, Doorduijn JK, Kater AP, **Dinmohamed AG**. Survival continues to increase in chronic lymphocytic leukemia: a population-based analysis among 19,131 patients diagnosed in the Netherlands between 1989 and 2015. EHA, European Hematology Association Congres; 14-17 juni 2018; Stockholm.

**van der Straten L**, Levin MD, van den Broek E, **Visser O**, Posthuma EF, Doorduijn JK, Kater AP, **Dinmohamed AG**. The value of rituximab-containing chemotherapy in second-line with or without previous rituximab exposure: a population-based study among patients with chronic lymphocytic leukemia in the Netherlands. EHA, European Hematology Association Congres; 14-17 juni 2018; Stockholm.

## 6.5 Presentaties en abstracts

**Arts LP, Oerlemans S, Horevoorts NJ, van de Poll-Franse LV**. Am I normal?' Patients with lymphoma wish to compare their patient-reported outcomes with those of their peers. ARPH, Association for Researches in Psychology and Health Congres; 25-26 januari 2018; Tilburg.

**Brink M**. Hematopoiesis myeloid 4: when performance of cytogenetics matters. DHC, Dutch Hematology Congres; 24-26 januari 2018; Arnhem.

**Dinmohamed AG**. Incidence treatment and survival of hairy-cell leukemia in the Netherlands. DHC, Dutch Hematology Congres; 24-26 januari 2018; Arnhem.

**Dinmohamed AG**. Treatment and relative survival in very elderly dlbc1 patients the Netherlands. DHC, Dutch Hematology Congres; 24-26 januari 2018; Arnhem.



## 7 Hoofdhalskanker

### 7.1 Publicaties met impactfactor

Boeve K, Schepman KP, Schuurin E, Roodenburg JL, Halmos GB, [van Dijk BA](#), Boorsma RA, de Visscher JG, Brouwers AH, van der Vegt B, Witjes MJ. High sensitivity and negative predictive value of sentinel lymph node biopsy in a retrospective early stage oral cavity cancer cohort in the Northern Netherlands. *Clin Otolaryngol*. 2018 Mar 25. doi: 10.1111/coa.13107. [Epub ahead of print]  
Impactfactor: 2,696

Kuijpers JH, [Louwman MW](#), Takes R, Slootweg PJ, Burdorf A, [van Dijk BA](#). Sinonasal cancer in The Netherlands: Follow-up of a population-based study 1989-2014 and incidence of occupation-related adenocarcinoma. *Head Neck*. 2018 Nov;40(11):2462-2468. doi: 10.1002/hed.25374. Epub 2018 Oct 15.  
Impactfactor: 2,471

Kuip EJ, Oldenmenger WH, Oomen-de Hoop E, Verduijn GM, Thijs-Visser MF, de Bruijn P, van Meerten E, Koolen SL, Mathijssen RH, [van der Rijt CC](#). Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy. *Cancers (Basel)*. 2018 Nov 15;10(11). pii: E445. doi: 10.3390/cancers10110445.  
Impactfactor: 5,326

[Mols F](#), Schoormans D, Smit JW, Netea-Maier RT, Links TP, van der Graaf WT, Husson O. Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES Registry. *Head Neck*. 2018 May 13. doi: 10.1002/hed.25325. [Epub ahead of print]  
Impactfactor: 2,471

Orlandi E, Alfieri S, Simon C, Trama A, Licitra L; RARECAREnet Working Group ([Visser O](#)). Treatment challenges in and outside a network setting: Head and neck cancers. *Eur J Surg Oncol*. 2019 Jan;45(1):40-45. doi: 10.1016/j.ejso.2018.02.007. Epub 2018 Feb 14. Review.  
Impactfactor: 3,688

van den Bovenkamp K, Dorgelo B, Noordhuis MG, van der Laan BF, van der Vegt B, Bijl HP, Roodenburg JL, [van Dijk BA](#), Oosting SF, Schuurin EM, Langendijk JA, Halmos GB, Plaat BE. Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus. *Oral Oncol*. 2018 Feb;77:131-136. doi: 10.1016/j.oraloncology.2017.12.017. Epub 2018 Jan 8.  
Impactfactor: 4,636

van Overveld LF, Takes RP, Turan AS, Braspenning JC, Smeele LE, Merx MA, Hermens RP; Dutch Head and Neck Audit Group ([van Dijk BA](#)). Needs and preferences of patients with head and neck cancer in integrated care. *Clin Otolaryngol*. 2018 Apr;43(2):553-561. doi: 10.1111/coa.13021.  
Impactfactor: 2,696

van Overveld LF, Takes RP, Braspenning JC, Baatenburg de Jong RJ, de Boer JP, Brouns JJ, Bun RJ, Dik EA, [van Dijk BA](#), van Es RJ, Hoebbers FJ, Kolenaar B, Kropveld A, Langeveld TP, Verschuur HP, de Visscher JG, van Weert S, Witjes MJ, Smeele LE, Merx MA, Hermens RP. Variation in Integrated Head and Neck Cancer Care: Impact of Patient and Hospital Characteristics. *Natl Compr Canc Netw*. 2018 Dec;16(12):1491-1498. doi: 10.6004/jnccn.2018.7061.  
Impactfactor: 6,471

Wedman J, Pruim J, van der Putten L, Hoekstra OS, de Bree R, [van Dijk BA](#), van der Laan BF. Is C-11 Methionine PET an alternative to 18-F FDG PET for identifying recurrent laryngeal cancer after radiotherapy? *Clin Otolaryngol*. 2018 Oct 12. doi: 10.1111/coa.13242. [Epub ahead of print]  
Impactfactor: 2,696

---

## 7.2 Posters

**Campschroer G**, Halmos GB, Merkx MA, **van Dijk BA**. Patient and tumor characteristics of patients with epithelial head and neck cancer by referral status to a head and neck oncology center in a nationally centralized setting. ECHNO, European Congress on Head and Neck Oncology; 11-14 april 2018; Rome.

## 8 Huidkanker

### 8.1 Publicaties met impactfactor

de Vries E, Misirli Y, Nijsten T, [Hollestein LM](#). Treatment and frequency of follow-up of BCC patients in the Netherlands. *J Eur Acad Dermatol Venereol*. 2018 Sep;32(9):e351-e354. doi: 10.1111/jdv.14924. Epub 2018 Apr 11. No abstract.  
Impactfactor: 4,287

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJ, van Akkooi AC, van den Berkmortel FW, van den Eertwegh AJ, de Groot JW, van der Hoeven KJ, Hospers GA, Kapiteijn E, Koornstra R, Kruit WH, [Louwman MW](#), Piersma D, van Rijn RS, Suijkerbuijk KP, Ten Tije AJ, Vreugdenhil G, Wouters MW, van Zeijl M, Haanen JB, Uyl-de Groot CA. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. *Anticancer Drugs*. 2018 Apr 9. doi: 10.1097/CAD.0000000000000628. [Epub ahead of print]  
Impactfactor: 1,869

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJ, van Akkooi AC, van den Berkmortel FW, van den Eertwegh AJ, Groenewegen G, de Groot JW, Haanen JB, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, [Louwman MW](#), Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, Uyl-de Groot CA, van der Hoeven KJ. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. *Anticancer Drugs*. 2018 Apr 13. doi: 10.1097/CAD.0000000000000629. [Epub ahead of print]  
Impactfactor: 1,869

Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, Chirlaque MD, Coza D, Galceran J, Gavin A, Hackl M, Katalinic A, Larønningen S, [Louwman MW](#), Morgan E, Robsahm TE, Sanchez MJ, Tryggvadóttir L, Tumino R, Van Eycken E, Vernon S, Zadnik V, Rosso S. Trends in incidence of thick, thin and in situ melanoma in Europe. *Eur J Cancer*. 2018 Mar;92:108-118. doi: 10.1016/j.ejca.2017.12.024. Epub 2018 Jan 31.  
Impactfactor: 7,191

Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, van Zeijl MC, Aarts MJ, van Akkooi AC, van den Berkmortel FW, Blokk WA, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, [Louwman MW](#), Piersma D, van Rijn RS, Suijkerbuijk KP, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ. Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. *Melanoma Res*. 2018 May 10. doi: 10.1097/CMR.0000000000000453. [Epub ahead of print]  
Impactfactor: 3,135

Sommariva A, Forsea AM, Agius D, Ascierto PA, Bastiaannet E, Borgognoni L, Demetriou A, Garbe C, Gavric Z, Hocevar M, Innos K, Larønningen S, [Louwman MW](#), Robsahm TE, Rutkwski P, van Akkooi A, Zorzi M, Pasquali S, van de Velde C, Rossi CR. Quality assurance in melanoma care: The EU-MELACARE study. *Eur J Surg Oncol*. 2018 Jul 3. pii: S0748-7983(18)31164-8. doi: 10.1016/j.ejso.2018.06.020. [Epub ahead of print]  
Impactfactor: 3,688

Vis K, Waalboer-Spuij R, Snels DG, [Hollestein LM](#). Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL). *Dermatology*. 2018 Jun 15:1-6. doi: 10.1159/000489118. [Epub ahead of print]  
Impactfactor: 1,958

### 8.2 Presentaties en abstracts

Leeneman B, Blommestein H, de Groot S, Holleman MS, Kuppen M, [Luyendijk M](#), Westgeest HM, Uyl-de Groot CA, Franken M. Reporting follow-up in survival analyses: informative or not? ISPOR Conference; 10-14 november 2018; Barcelona.

## 9 Longkanker

### 9.1 Publicaties met impactfactor

Berge MT, Beck N, Heineman DJ, **Damhuis RA**, Steup WH, van Huijstee PJ, Eerenberg JP, Veen E, Maat A, Versteegh M, van Brakel T, Schreurs WH, Wouters MW. **Dutch Lung Surgery Audit: A National Audit Comprising Lung and Thoracic Surgery Patients**. *Ann Thorac Surg*. 2018 Apr 21. pii: S0003-4975(18)30544-7. doi: 10.1016/j.athoracsur.2018.03.049. [Epub ahead of print]  
Impactfactor: 3,779

Blaauwgeers H, **Damhuis RA**, Lissenberg-Witte B, de Langen AJ, Senan S, Thunnissen E. **A population-based study of outcomes in surgically resected T3N0 non-small cell lung cancer in the Netherlands, defined using TNM-7 and TNM-8; justification of changes and an argument to incorporate histology in the staging algorithm?** *J Thorac Oncol*. 2018 Nov 5. pii: S1556-0864(18)33413-0. doi: 10.1016/j.jtho.2018.10.164. [Epub ahead of print]  
Impactfactor: 10,336

**Damhuis RA**, van Meerbeeck JP. **International trends in the clinical epidemiology of malignant pleural mesothelioma**. *J Thorac Dis*. 2018 Mar;10(3):1147-1148. doi: 10.21037/jtd.2018.03.26. No abstract available.  
Impactfactor: 1,804

den Bakker MA, **Damhuis RA**. **Pentameric last digit preference and stage border avoidance in pathology measurement**. *Histopathology*. 2018 Apr 27. doi: 10.1111/his.13640. [Epub ahead of print]  
Impactfactor: 3,267

Derks JL, Dingemans AC, van Suylen RJ, den Bakker MA, **Damhuis RA**, van den Broek EC; PALGA-group, Speel EJ, Thunnissen E. **Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimen?** *Histopathology*. 2018 Nov 28. doi: 10.1111/his.13800. [Epub ahead of print]  
Impactfactor: 3,267

Detillon DD, Driessen EJ, **Aarts MJ**, Janssen-Heijnen ML, van Eijck CH, Veen EJ. **Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery**. *Eur J Cancer*. 2018 Jul 12;101:30-37. doi: 10.1016/j.ejca.2018.06.016. [Epub ahead of print]  
Impactfactor: 7,191

Kuijpers CC, Hendriks LE, Derks JL, Dingemans AC, van Lindert AS, van den Heuvel MM, **Damhuis RA**, Willems SM. **Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer**. *Lung Cancer*. 2018 Jul;121:76-81. doi: 10.1016/j.lungcan.2018.05.006. Epub 2018 May 15.  
Impactfactor: 4,486

Rich A, Baldwin D, Alfigeme I, Beckett P, Berghmans T, Brincat S, Burghuber O, Corlateanu A, Cufer T, **Damhuis RA**, Danila E, Domagala-Kulawik J, Elia S, Gaga M, Goksel T, Grigoriu B, Hillerdal G, Huber RM, Jakobsen E, Jonsson S, Jovanovic D, Kavcova E, Konsoulova A, Laisaar T, Makitaro R, Mehic B, Milroy R, Moldvay J, Morgan R, Nanushi M, Paesmans M, Putora PM, Samarzija M, Scherpereel A, Schlessler M, Sculier JP, Skrickova J, Sotto-Mayor R, Strand TE, Van Schil P, Blum TG. **Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries**. *BMC Cancer*. 2018 Nov 20;18(1):1144. doi: 10.1186/s12885-018-5009-y.  
Impactfactor: 3,288

von Meyenfeldt EM, Marres GM, van Thiel E, **Damhuis RA**. **Variation in length of hospital stay after lung cancer surgery in the Netherlands**. *Eur J Cardiothorac Surg*. 2018 Mar 5. doi: 10.1093/ejcts/ezy074. [Epub ahead of print]  
Impactfactor: 3,504

## 9.2 Overige publicaties

Burgers JA, [Damhuis RA](#). 30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? ERJ Open Res. 2018 Nov 5;4(4). pii: 00030-2018. doi: 10.1183/23120541.00030-2018. eCollection 2018 Oct.

Kuijpers CC, van den Heuvel MM, Overbeek LI, van Slooten HJ, van Lindert AS, [Damhuis RA](#), Willems SM. Landelijke variatie in moleculaire diagnostiek bij gemetastaseerde longkanker. Ned Tijdschr Geneeskd. 2018 Dec 5;162. pii: D1607.

## 9.3 Posters

Driessen EJ, Detillon DE, Bootsma GP, de Ruyscher DK, Veen EJ, [Aarts MJ](#), Janssen-Heijnen ML. Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older. SIOG, International Society of Geriatric Oncology Annual Conference; 16-18 november 2018; Amsterdam.

## 9.4 Presentaties en abstracts

[Douma G](#), [Fransen H](#), Venmans B, [Aarts MJ](#). End of life treatment of metastatic lung cancer patients in the Netherlands: a population-based study. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

## 10 Neuro-endocriene tumoren

### 10.1 Publicaties met impactfactor

Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, de Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Maria BP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, [van Eycken E, van der Zwan JM](#), Žagar T, Giacomelli L, Miceli R; NEPscore Working Group ([Siesling S, van Dijk BA, Visser O](#)). A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer*. 2018 Mar 20. pii: ERC-17-0489. doi: 10.1530/ERC-17-0489. [Epub ahead of print] Impactfactor: 5,331

[van der Zwan JM, Siesling S](#), van Velthuysen L, Links T, Walenkamp A, Tesselaar M. Extra-Pulmonary Neuroendocrine Carcinomas: A Population-Based Study in the Netherlands. *Neuroendocrinology*. 2018 Apr 14;107(1):50-59. doi: 10.1159/000488987. [Epub ahead of print] Impactfactor: 5,024

# 11 Neuro-oncologie

## 11.1 Publicaties met impactfactor

Bollen L, Jacobs WC, van der Linden YM, [van der Hel O](#), Taal W, Dijkstra PD. A systematic review of prognostic factors predicting survival in patients with spinal bone metastases. *Eur Spine J*. 2018 Apr;27(4):799-805. doi: 10.1007/s00586-017-5320-3. Epub 2017 Oct 24. Review. Impactfactor: 2,132

Bollen L, Dijkstra SP, Bartels RH, de Graeff A, Poelma DL, Brouwer T, Algra PR, Kuijlen JM, Minnema MC, Nijboer C, Rolf C, Sluis T, Terheggen MA, [van der Togt-van Leeuwen AC](#), van der Linden YM, Taal W. Clinical management of spinal metastases-The Dutch national guideline. *Eur J Cancer*. 2018 Oct 15;104:81-90. doi: 10.1016/j.ejca.2018.08.028. [Epub ahead of print] Review. Impactfactor: 7,191

Groenen KH, van der Linden YM, Brouwer T, Dijkstra SP, de Graeff A, Algra PR, Kuijlen JM, Minnema MC, Nijboer C, Poelma DL, Rolf C, Sluis T, Terheggen MA, [van der Togt-van Leeuwen AC](#), Bartels RH, Taal W. The Dutch national guideline on metastases and hematological malignancies localized within the spine; a multidisciplinary collaboration towards timely and proactive management. *Cancer Treat Rev*. 2018 May 29;69:29-38. doi: 10.1016/j.ctrv.2018.05.013. [Epub ahead of print] Review. Impactfactor: 8,122

Rodenburg RJ, Hanssens PE, [Ho VK](#), Beerepoot LV. Validation of the Chowdhury overall survival score in patients with melanoma brain metastasis treated with Gamma Knife Radiosurgery. *J Neurooncol*. 2018 Feb 22. doi: 10.1007/s11060-018-2808-6. [Epub ahead of print] Impactfactor: 3,060

## 11.2 Posters

[de Peuter MA](#), van Baest L, Bienfait HP, Dujardin K, Hanse MC, [Vos MJ](#), de Vos FY, [Ho VK](#), Gijtenbeek JM. Quality criteria for glioma care, use in clinical practice: results of a national survey. EANO, European Association of Neuro-Oncology Meeting; 10-14 oktober 2018; Stockholm.

## 12 Upper GI & HPB

### 12.1 Publicaties met impactfactor

Brenkman HJ, **van Putten M**, Visser E, **Verhoeven RH**, Nieuwenhuijzen GA, Slingerland M, van Hillegersberg R, **Lemmens VE**, Ruurda JP. Timing of postoperative chemotherapy in patients undergoing perioperative chemotherapy and gastrectomy for gastric cancer. *Surg Oncol*. 2018 Sep;27(3):421-427. doi: 10.1016/j.suronc.2018.05.026. Epub 2018 May 30. Impactfactor: 2,558

Claassen YH, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, **Verhoeven RH**, van Eycken E, de Schutter H, Johansson J, Rouvelas I, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Allum WH, Portielje JE, Bastiaannet E, van de Velde CJ. North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis. *Eur J Surg Oncol*. 2018 Oct 16. pii: S0748-7983(18)31433-1. doi: 10.1016/j.ejso.2018.09.014. [Epub ahead of print] Impactfactor: 3,688

de Rooij T, van Hilst J, van Santvoort H, Boerma D, van den Boezem P, Daams F, van Dam R, Dejong C, van Duyn E, Dijkgraaf M, van Eijck C, Festen S, Gerhards M, Groot Koerkamp B, **de Hingh I**, Kazemier G, Klaase J, de Kleine R, van Laarhoven C, Luyer M, Patijn G, Steenvoorde P, Suker M, Abu Hilal M, Busch O, Besselink M; Dutch Pancreatic Cancer Group. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled Trial. *Ann Surg*. 2018 Aug 3. doi: 10.1097/SLA.0000000000002979. [Epub ahead of print] Impactfactor: 9,203

Genc CG, Klumpen HJ, **van Oijen MG**, van Eijck CH, Nieveen van Dijkum EJ. A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands. *World J Surg*. 2018 Feb;42(2):490-497. doi: 10.1007/s00268-017-4278-y. Impactfactor: 2,766

Goense L, Visser E, Haj Mohammad N, Mook S, **Verhoeven RH**, Meijer GJ, van Rossum PS, Ruurda JP, van Hillegersberg R. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study. *Eur J Surg Oncol*. 2018 Feb 13. pii: S0748-7983(18)30415-3. doi: 10.1016/j.ejso.2018.02.005. [Epub ahead of print] Impactfactor: 3,688

Groen JV, Sibinga Mulder BG, van Eycken E, Valerianova Z, Borrás JM, **van der Geest LG**, Capretti G, Schlesinger-Raab A, Primic-Zakelj M, Ryzhov A, van de Velde CJ, Bonsing BA, Bastiaannet E, Mieog JS. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. *Ann Surg Oncol*. 2018 Aug 27. doi: 10.1245/s10434-018-6705-1. [Epub ahead of print] Impactfactor: 3,857

Huang L, Jansen L, Balavarca Y, **van der Geest LG**, **Lemmens VE**, Van Eycken L, De Schutter H, Johannesen TB, Primic-Zakelj M, Zadnik V, Mägi M, Pulte D, Schrotz-King P, Brenner H. Non-surgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: A large international population-based study. *Int J Cancer*. 2018 Jun 20. doi: 10.1002/ijc.31628. [Epub ahead of print] Impactfactor: 7,360

Huang L, Jansen L, Balavarca Y, Babaei M, **van der Geest LG**, **Lemmens VE**, Van Eycken L, De Schutter H, Johannesen TB, Primic-Zakelj M, Zadnik V, Besselink MG, Schrotz-King P, Brenner H. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. *BMC Med*. 2018 Aug 21;16(1):125. doi: 10.1186/s12916-018-1120-9. Impactfactor: 9,088



Koëter M, **van Putten M**, **Verhoeven RH**, **Lemmens VE**, Nieuwenhuijzen GA. Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival. *Acta Oncol*. 2018 Mar 12;1-9. doi: 10.1080/0284186X.2018.1450521. [Epub ahead of print]  
Impactfactor: 3,473

Mackay TM, **van Erning FN**, **van der Geest LG**, de Groot JW, Haj Mohammad N, **Lemmens VE**, van Laarhoven HW, Besselink MG, Wilmink JW; Dutch Pancreatic Cancer Group. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. *Eur J Cancer*. 2018 Nov 23;106:99-105. doi: 10.1016/j.ejca. 2018.10.008. [Epub ahead of print]  
Impactfactor: 7,191

Nelen SD, Bosscha K, **Lemmens VE**, Hartgrink HH, **Verhoeven RH**, de Wilt JH; Dutch Upper Gastrointestinal Cancer Audit group. Morbidity and mortality according to age following gastrectomy for gastric cancer. *Br J Surg*. 2018 Apr 23. doi: 10.1002/bjs.10836. [Epub ahead of print]  
Impactfactor: 5,433

**van der Geest LG**, van Eijck CH, Groot Koerkamp B, **Lemmens VE**, Busch OR, **Vissers PA**, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. *Cancer Med*. 2018 Sep 6. doi: 10.1002/cam4.1750. [Epub ahead of print]  
Impactfactor: 3,202

van der Graaf WT, Tielen R, Bonenkamp JJ, **Lemmens VE**, **Verhoeven RH**, de Wilt JH. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. *Br J Surg*. 2018 Apr 17. doi: 10.1002/bjs.10809. [Epub ahead of print]  
Impactfactor: 5,433

van der Werf LR, Dikken JL, van Berge Henegouwen MI, **Lemmens VE**, Nieuwenhuijzen GA, Wijnhoven BP; Dutch Upper GI Cancer Audit group. A Population-based Study on Lymph Node Retrieval in Patients with Esophageal Cancer: Results from the Dutch Upper Gastrointestinal Cancer Audit. *Ann Surg Oncol*. 2018 May;25(5):1211-1220. doi: 10.1245/s10434-018-6396-7. Epub 2018 Mar 9.  
Impactfactor: 3,857

van der Werf LR, Dikken JL, van der Willik EM, van Berge Henegouwen MI, Nieuwenhuijzen GAP, Wijnhoven BP; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group (**Lemmens VE**). Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study. *Eur J Cancer*. 2018 Mar;91:76-85. doi: 10.1016/j.ejca.2017.12.009. Epub 2018 Jan 30.  
Impactfactor: 7,191

**van Erning FN**, Mackay TM, **van der Geest LG**, Groot Koerkamp B, van Laarhoven HW, Bonsing BA, Wilmink JW, van Santvoort HC, de Vos-Geelen J, van Eijck CH, Busch OR, **Lemmens VE**, Besselink MG; Dutch Pancreatic Cancer Group. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. *Acta Oncol*. 2018 Sep 28;1-8. doi: 10.1080/0284186X.2018.1518593. [Epub ahead of print]  
Impactfactor: 3,473

**van Putten M**, de Vos-Geelen J, Nieuwenhuijzen GA, Siersema PD, **Lemmens VE**, Rosman C, van der Sangen MJ, **Verhoeven RH**. Long-term survival improvement in oesophageal cancer in the Netherlands. *Eur J Cancer*. 2018 Mar 20;94:138-147. doi: 10.1016/j.ejca.2018.02.025. [Epub ahead of print]  
Impactfactor: 7,191

**van Putten M**, Johnston BT, Murray LJ, Gavin AT, McManus DT, Bhat S, Turkington RC, Coleman HG. 'Missed' oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus patients: A large population-based study. *United European Gastroenterol J*. 2018 May;6(4):519-528. doi: 10.1177/2050640617737466. Epub 2017 Oct 11.  
Impactfactor: 3,477

**van Putten M**, Nelen SD, **Lemmens VE**, Stoot JH, Hartgrink HH, Gisbertz SS, Spillenaar Bilgen EJ, Heisterkamp J, **Verhoeven RH**, Nieuwenhuijzen GA. Overall survival before and after centralization of gastric cancer surgery in the Netherlands. *Br J Surg*. 2018 Aug 22. doi: 10.1002/bjs.10931. [Epub ahead of print]  
Impactfactor: 5,433

Versteeg SE, **Ho VK**, **Siesling S**, Varkevisser M. Centralisation of cancer surgery and the impact on patients' travel burden. *Health Policy*. 2018 Jul 6. pii: S0168-8510(18)30217-3. doi: 10.1016/j.healthpol.2018.07.002. [Epub ahead of print]  
Impactfactor: 2,293

Weberpals J, Jansen L, Silversmit G, Verbeeck J, **van der Geest LG**, **Vissers PA**, Zadnik V, Brenner H. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients. *Clin Epidemiol*. 2018 Aug 30;10:1109-1125. doi: 10.2147/CLEP.S160973. eCollection 2018.  
Impactfactor: 3,799

**Zijlstra M**, **van der Geest LG**, van Laarhoven HW, **Lemmens VE**, **van de Poll-Franse LV**, **Raijmakers NJ**. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. *Acta Oncol*. 2018 May 9:1-7. doi: 10.1080/0284186X.2018.1470330. [Epub ahead of print]  
Impactfactor: 3,473

## 12.2 Overige publicaties

**van Putten M**, **Verhoeven RH**, Koëter M, van Laarhoven HW, van Sandick JW, Plukker JT, Siersema PD, Hulshof MC, Wijnhoven BP, **Lemmens VE**, Nieuwenhuijzen GA. Ziekenhuis van diagnose beïnvloedt kans op curatieve behandeling voor slokdarm-en maagkanker. *Ned Tijdsch Geneesk* 2018 Maart 24:162(12);10-15.

## 12.3 Proefschriften en promoties

Koëter M. The influence of treatment decisions on the outcome of esophageal cancer. Rotterdam: Erasmus Universiteit; 29 juni 2018. Promotor: **VE Lemmens**, HJ Rutten. Co-promotoren: **RH Verhoeven**, GA Nieuwenhuijzen.

Nelen SD. Surgical and epidemiological aspects in gastric cancer patients: the role of age centralization and palliative treatment. EL. Tying a Surgical Knot in Breast Cancer Outcomes. Nijmegen: Radboud Universiteit; 9 november 2018. Promotoren: JH de Wilt, **VE Lemmens**. Copromotoren: K Bosscha, **RH Verhoeven**.

**van Putten M**. Oesophageal and gastric cancer: optimising care and outcomes in changing clinical practice. Rotterdam: Erasmus Universiteit; 25 mei 2018. Promotor: **VE Lemmens**. Overige leden: MJ Bruno, GA Hospers, JJ van Lanschot. Co-promotoren: GA Nieuwenhuijzen, **RH Verhoeven**.

## 12.4 Posters

**Dijksterhuis WP**, **Verhoeven RH**, van Oijen MG, van Laarhoven HW. Diversity of first-line palliative systemic treatments for esophagogastric cancer patients with synchronous metastases: a real world evidence study. ASCO Annual Meeting; 1-5 juni 2018; Chicago.

**Dijksterhuis WP**, **Verhoeven RH**, van Oijen MG, van Laarhoven HW. Diversity of first-line palliative systemic treatments for gastroesophageal cancer patients with synchronous metastases: a real world evidence study. European Gastric Cancer Congress; 7-8 juni; Leiden.

Huang L, Jansen L, Balavarca Y, **van der Geest LG**, **Lemmens VE**, van Eycken L, de Schutter H, Johannesen TB, Primic-Zakelj M, Zadnik V, Mägi M, Pulte D, Schrotz-King P, Brenner H. Chemotherapy and radiotherapy application for pancreatic cancer in Europe and USA: an international population-based study. ASCO Annual Meeting; 1-5 juni 2018; Chicago.

van den Boorn H, Abu-Hanna A, ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Hoon Park S, Dutton SJ, Bang YJ, Mohammad NH, Sprangers MA, **Verhoeven RH**, Zwinderman AH, van Oijen MG, van Laarhoven HW. Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer. ASCO Annual Meeting; 1-5 juni 2018; Chicago.

**Zijlstra M, van der Geest LG**, van Laarhoven HW, **Lemmens VE, van de Poll-Franse LV, Raijmakers NJ**. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. EAPC, European Association for Palliative Care World Research Congress; 24-26 mei 2018; Bern.

## 12.5 Presentaties en abstracts

Claassen Y, Bastiaannet E, Hartgrink H, Dikken J, de Steur W, Slingerland M, **Verhoeven RH**, van Eycken E, de Schutter H, Lindblad M, Hedberg J, Johnson E, Hjortland GO, Jensen L, Larsson H, Koessler T, Chevallay M, Allum W, van de Velde C. International comparison of treatment strategy in metastatic gastric cancer: a survey from the EURECCA Upper GI group. ESSO, The European Society of Surgical Oncology Congress; 10-12 oktober 2018; Boedapest.

**Dijksterhuis W, Verhoeven RH**, van Oijen MG, van Laarhoven HW. Diversity of first-line palliative systemic treatments for esophagogastric cancer patients with synchronous metastases. ENCR, European Network of Cancer Registries Scientific Meeting and General Assembly; 26-28 september 2018; Kopenhagen.

Groen JV, Mulder BS, van Eycken E, Valerianova Z, Borrás JM, **van der Geest LG**, Capretti G, Schlesinger-Raab A, Primic Zakelj M, Ryzhov A, van de Velde C, Bonsing B, Bastiaannet E, Mieog S. Differences in treatment and outcome of pancreatic adenocarcinoma stage I and II in the EURECCA pancreas consortium. ESSO, The European Society of Surgical Oncology Congress; 10-12 oktober 2018; Boedapest.

Groen JV, van Eycken E, Valerianova Z, Borrás JM, **van der Geest LG**, Capretti G, Schlesinger-Raab A, Primic Zakelj M, Ryzhov A, Mieog S. Differences in treatment and outcome of pancreatic adenocarcinoma stage I & II in the EURECCA pancreas consortium. IHPBA World Congress, International Hepato-Pancreatic Biliary Association; 4-7 september 2018; Genève.

Huang L, Jansen L, Balavarca Y, Babaei M, **van der Geest LG, Lemmens VE**, van Eycken L, de Schutter H, Johannesen TB, Primic-Zakelj M, Zadnik V, Schrotz-King P, Brenner H. Survival of resected and overall pancreatic cancer patients in Europe and USA 2003-2014: an international large-scale population-based investigation. ASCO Annual Meeting; 1-5 juni 2018; Chicago.

MacKay TM, **van Erning FN, van der Geest LG**, Groot Koerkamp B, van Laarhoven HW, Bonsing B, Wilmink J, van Santvoort H, de Vos-Geelen J, van Eijck CH, Busch OR, **Lemmens VE**, Besselink MG. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. EPC, European Pancreatic Club jubilee meeting; 13-16 juni 2018; Berlijn.

MacKay TM, **van Erning FN, van der Geest LG**, Groot Koerkamp B, van Laarhoven HW, de Vos-Geelen J, van Eijck CH, Busch OR, **Lemmens VE**, Besselink MG. Influence of the location (head, body, tail) of pancreatic ductal adenocarcinoma on tumor stage, treatment and survival: a population-based analysis. IHPBA World Congress, International Hepato-Pancreatic Biliary Association; 4-7 september 2018; Genève.

Nelen SD, Bosscha K, **Lemmens VE**, Hartgrink A, **Verhoeven RH**, de Wilt H. A clinical risk score for post-operative morbidity and mortality in young and elderly gastric cancer patients. SSO, Society Surgical Oncology Symposium; 21-24 maart 2018; Chicago, Illinois.

Strijker M, Belkouz A, **van der Geest LG**, Busch OR, van Gulik TM, Verheij J, Wilmink JW, Groot Koerkamp B, Klumpen HJ, Besselink MG. Nationwide treatment, outcome and predictors for survival in distal cholangiocarcinoma. IHPBA World Congress, International Hepato-Pancreatic Biliary Association; 4-7 september 2018; Genève.

---

van Kleef JJ, ter Veer E, van den Doorn H, Prins M, Ngai LL, Mohammad NH, **van de Poll-Franse LV**, Zwinderman A, van Oijen M, van Laarhoven H, Sprangers M. Health-related quality of life during palliative systemic therapy for oesophagogastric cancer: a systematic review. ISOQOL Annual Conference, International Society for Quality of Life Research; 24-27 oktober 2018; Dublin.

van Tienhoven G, Versteijne E, Suker M, **Groothuis KB**, Busch OR, Bonsing BA, de Hingh IH, Festen S, Patijn GA, de Vos-Geelen J, Zwinderman AH, Punt CJ, van Eijck CH. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. ASCO Annual Meeting; 1-5 juni 2018; Chicago.

**Verhoeven RH**. Regional and hospital variation in gastric treatment. European Gastric Cancer Congres; 7-8 juni; Leiden.

**Zijlstra M, van der Geest LG**, van Laarhoven HW, **Lemmens VE, van de Poll-Franse LV, Raijmakers NJ**. Best supportive care for patients with pancreatic cancer: patient characteristics and treatment considerations: a population-based study in the Netherlands. EAPC, European Association for Palliative Care World Research Congres; 24-26 mei 2018; Bern.

## 13 Urogenitale kanker

### 13.1 Publicaties met impactfactor

Barbosa AL, Vermeulen SH, **Aben KK**, Grotenhuis AJ, Vrieling A, Kiemeney LA. Smoking intensity and bladder cancer aggressiveness at diagnosis. *PLoS One*. 2018 Mar 23;13(3):e0194039. doi: 10.1371/journal.pone.0194039. eCollection 2018. Impactfactor: 2,766

Cuypers M, Lamers RE, Kil PJ, **van de Poll-Franse LV**, de Vries M. Impact of a web-based prostate cancer treatment decision aid on patient-reported decision process parameters: results from the Prostate Cancer Patient Centered Care trial. *Support Care Cancer*. 2018 May 12. doi: 10.1007/s00520-018-4236-8. [Epub ahead of print] Impactfactor: 2,676

Cuypers M, Lamers RE, Kil PJ, **van de Poll-Franse LV**, de Vries M. Longitudinal regret and information satisfaction after deciding on treatment for localized prostate cancer with or without a decision aid. Results at one-year follow-up in the PCPCC trial. *Patient Educ Couns*. 2018 Oct 4. pii: S0738-3991(18)30843-7. doi: 10.1016/j.pec.2018.10.006. [Epub ahead of print] Impactfactor: 2,785

Cuypers M, Lamers RE, Kil PJ, van Tol-Geerdink JJ, van Uden-Kraan CF, **van de Poll-Franse LV**, de Vries M. Uptake and usage of an online prostate cancer treatment decision aid in Dutch clinical practice: A quantitative analysis from the Prostate Cancer Patient Centered Care trial. *Health Informatics J*. 2018 Jun 1:1460458218779110. doi: 10.1177/1460458218779110. [Epub ahead of print] Impactfactor: 1,833

Hermans TJ, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP, Boormans JL, **Aben KK**, van der Heijden MS, Pos FJ, de Wit R, Beerepoot LV, **Verhoeven RH**, van Rhijn BW. Superior Efficacy of Neoadjuvant Chemotherapy and Radical Cystectomy in cT3-4aN0M0 compared to cT2N0M0 Bladder Cancer. *Int J Cancer*. 2018 Aug 28. doi: 10.1002/ijc.31833. [Epub ahead of print] No abstract available. Impactfactor: 7,36

**Jansen H**, van Oort IM, van Andel G, Wijsman BP, Pos FJ, Hulshof MC, Hulsbergen-van de Kaa CA, van Leenders GJ, Fütterer JJ, Somford DM, Busstra MB, van Moorselaar RJ, Kiemeney LA, **Aben KK**. Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. *Prostate Cancer Prostatic Dis*. 2018 Nov 14. doi: 10.1038/s41391-018-0109-y. [Epub ahead of print] Impactfactor: 4,099

**Lancee M**, Tikkinen KA, de Reijke TM, Kataja VV, **Aben KK**, **Vernooij RW**. Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer. *BJU Int*. 2018 Apr 7. doi: 10.1111/bju.14237. [Epub ahead of print] Review. Impactfactor: 4,688

Nicolai N, BIASONI D, Catanzaro MA, Colecchia M, Trama A; RARECAREnet Working Group (**Visser O**). Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. *Eur J Surg Oncol*. 2019 Jan;45(1):60-66. doi: 10.1016/j.ejso.2018.02.006. Epub 2018 Feb 14. Review. Impactfactor: 3,688

Tikkinen KA, Dahm P, Lytvyn L, Heen AF, **Vernooij RW**, Siemieniuk RA, Wheeler R, Vaughan B, Fobuzi AC, Blanker MH, Junod N, Sommer J, Stirnemann J, Yoshimura M, Auer R, MacDonald H, Guyatt G, Vandvik PO, Agoritsas T. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. *BMJ*. 2018 Sep 5;362:k3581. doi: 10.1136/bmj.k3581. No abstract available. Impactfactor: 23,562

**Vernooij RW**, van Oort I, de Reijke TM, **Aben KK**. Nationwide treatment patterns and survival of older patients with prostate cancer. *Journal of Geriatric Oncology*. 2018 Jul; 9(4). doi: 10.1016/j.jgo.2018.06.010.  
Impactfactor: 3,359

**Vernooij RW**, Lytvyn L, Pardo-Hernandez H, Albarqouni L, Canelo-Aybar C, Campbell K, Agoritsas T. Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review. *BMJ Open*. 2018 Sep 5;8(9):e025470. doi: 10.1136/bmjopen-2018-025470.  
Impactfactor: 2,413

### 13.2 Overige publicaties

Huetting TA, Cornel EB, Somford DM, **Jansen H**, van Basten JP, Pleijhuis RG, Korthorst RA, van der Palen JA, Koffijberg H. External validation of models predicting the probability of lymph node involvement in prostate cancer patients. *European Urology Oncology*. 2018 1;411-417.

Schepens MH, Ziedses des Planten CM, Somford DM, van Erkelens JA, Cremers RG, de Vries S, **Aben KK**, Hoekstra R, Stienen JJ, Wijsman BP, Busstra MB, van Limbeek J. Hoe vaak incontinentie na radicale prostatectomie: incidentie bepaald op basis van declaratie incontinentiemateriaal. *Ned Tijdsch Geneesk* 2018 April;162(9):D2294.

van Doeveren T, van Leeuwen PJ, **Aben KK**, van der Aa MA, Barendrecht M, Boevé ER, Cornel EB, van der Heijden AG, Hendricksen K, Hirdes W, Kooistra A, Kroon BK, Leliveld AM, Meijer RP, van Melick H, Merks B, de Reijke TM, de Vries P, Wymenga LF, Wijsman B, Boormans JL. Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: the REBACARE-trial. *Contemporary clinical trials communications* 2018 Mar;9:121-129.

van Valenberg FJ, Kajtazovic A, Canepa G, Lüdecke G, Kilb JI, **Aben KK**, Nativ O, Madaan S, Ayres B, Issa R, Witjes JA. Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study. *Bladder Cancer*. 2018 Oct 29;4(4):365-376. doi: 10.3233/BLC-180187.

**Vernooij RW**, Blanker MH. Prostaatankerscreening met de PSA-test: een klinische richtlijn. *Ned Tijdschr Geneesk*. 2018;162:D3527.

### 13.3 Proefschriften en promoties

Cuypers M. Choosing treatment for prostate cancer: Information provision, quality of life, and use of an online decision aid. Tilburg: Universiteit Tilburg; 18 mei 2018. Promotor: **LV van de Poll-Franse**.

### 13.4 Posters

**Jansen H**, Somford DM, van Oort IM, Hulshof MC, Pos FJ, van Moorselaar RJ, Wijsman BP, Hulsbergen-van de Kaa CA, Kiemeny LA, **Aben KK**. Variation in pelvic lymph node dissection among prostate cancer patients in the Netherlands: are we using a double standard for radical prostatectomy and radiotherapy patients? EAU, European Association of Urology Congress; 16-20 maart 2018; Kopenhagen.

**Vernooij RW**, **Jansen H**, van den Berkmortel FW, Hamberg AP, **Aben KK**. Chemohormonal therapy vs androgen deprivation therapy as mono-therapy in patients with metastatic prostate cancer at diagnosis: a population-based study in the Netherlands. WEON Congres, Werkgroep Epidemiologisch Onderzoek Nederland; 7-8 juni 2018; Bilthoven.

### 13.5 Presentaties en abstracts

Hermans TJ, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP, Boormans JL, **Aben KK**, van der Heijden MS, de Wit R, Beerepoot LV, **Verhoeven RH**, van Rhijn BW. Superieure effectiviteit van neoadjuvante chemotherapie en radicale cystectomie in cT3-4N0M0 blaascarcinoom ten opzichte van cT2N0M0 blaascarcinoom. NVU, Nederlandse Vereniging voor Urologie Voorjaarsvergadering; 25 mei 2018; Nijmegen.

**Jansen H**, Somford DM, van Oort IM, Hulshof MC, Pos FJ, van Moorselaar RJ, Wijsman BP, Hulsbergen-van de Kaa CA, Kiemeny LA, **Aben KK**. Variation in pelvic lymph node dissection among prostate cancer patients in the Netherlands: are we using a double standard for radical prostatectomy and radiotherapy patients? EAU, European Association of Urology Congress; 16-20 maart 2018; Kopenhagen.

Kuppen M, Westgeest HM, van den Eertwegh F, van Moorselaar J, de Wit R, van Oort I, **Aben KK**, **Verhoeven RH**, van den Bergh F, Coenen J, Uyl-de Groot C, Gerritsen W. Outcomes of crossover between androgen receptor targeting drugs in the castration resistant prostate cancer registry (CAPRI). EAU, European Association of Urology Congress; 16-20 maart 2018; Kopenhagen.

Kuppen M, Westgeest HM, van den Eertwegh A, Moorselaar R, Mehra N, Coenen J, van Oort I, van den Bergh A, **Aben KK**, Somford D, Lavalaye J, Gerritsen W, Uyl-de Groot C. Patient reported outcomes in the castration resistant prostate cancer registry (pro-capri) in the Netherlands. ISPOR Conference; 10-14 november 2018; Barcelona.

Tran M, **Aben KK**, Neves J, Fowler S, Sullivan M, Stewart G, Challacombe B, Mahrous A, Patki P, Mumtaz F, Barod R, Aitchison M, Bex A. Optimal surgery treatment of T1 renal tumours correlates with nephrectomy volume. BAUS, British Association of Urological Surgeons Annual Scientific Meeting; 25-28 juni 2018; Liverpool.

Violette P, **Vernooij RW**, Aoki Y, Agarwal A, Cartwright R, Arai Y, Tailly T, Novara G, Craigie S, Breau R, Sandset PM, Guyatt G, Tikkinen K. An international survey on the use of thromboprophylaxis in urological surgery. EAU, European Association of Urology Congress; 16-20 maart 2018; Kopenhagen.



## B1 Impactfactoren tijdschriften

Van de 211 peer-reviewed artikelen werd 92% gepubliceerd in een tijdschrift met een impactfactor. De maximale impactfactor bedroeg 53,254 en de gemiddelde impactfactor was 5,2. (de impactfactor is gebaseerd op 2017 Journal Citation Reports®).

**Tabel 1** Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Acta Oncologica	3,473	4
AJOG American Journal of Obstetrics & Gynecology	5,732	1
Annals of Plastic Surgery	1,536	1
Annals of Surgery	9,203	3
Annals of Surgical Oncology	3,857	4
Annals of Thoracic Surgery	3,779	1
Anti-cancer Drugs	1,869	2
BJC British Journal of Cancer	5,922	3
BJD British Journal of Dermatology	6,129	2
BJH British Journal of Haematology	5,128	1
BJS British Journal of Surgery	5,433	4
BJU International	4,688	3
Blood	15,132	2
BMC Cancer	3,288	4
BMC Health Services Research	1,843	1
BMC Medical Research Methodology	2,524	1
BMC Medicine	9,088	2
BMC Palliative Care	2,335	1
BMJ	23,562	1
BMJ Open	2,413	2
BMJ Supportive & Palliative Care	2,385	1
Breast Cancer Research and Treatment	3,605	1
British Journal of Sports Medicine	7,867	1
Cancer	6,537	4
Cancer Epidemiology	2,888	2
Cancer Epidemiology, Biomarkers & Prevention	4,554	1
Cancer Medicine	3,202	4
Cancer Treatment Reviews	8,122	1
Cancers (Basel)	5,326	1
Clinical Colorectal Cancer	3,861	1
Clinical Epidemiology	3,799	1
Clinical Gastroenterology and Hepatology	7,860	1
Clinical Oncology	3,055	1
Clinical Otolaryngology	2,696	3
Dermatology	1,958	1
Endocrine-Related Cancer	5,331	1
EJSO European Journal of Surgical Oncology	3,688	17
European Journal of Cancer	7,191	13
European Journal of Cardio-Thoracic Surgery	3,504	1

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
European Journal of Haematology	2,595	1
European Journal of Obstetrics & Gynecology and Reproduc. Biol.	1,809	1
European Journal of Oncology Nursing	1,812	1
European Journal of Radiology	2,843	1
European Radiology	4,027	3
European Spine Journal	2,132	1
Genes	3,191	1
Gynecologic Oncology	4,540	4
Head & Neck	2,471	2
Health and Quality of Life Outcomes	2,278	1
Health Informatics Journal	1,833	1
Health Policy	2,293	1
Histopathology	3,267	2
IJC International Journal of Cancer	7,360	6
International Journal of Gynecological cancer	2,192	1
International Journal of Molecular Sciences	3,687	1
JAAD Journal of the American Academy of Dermatology	6,898	1
JCE Journal of Clinical Epidemiology	4,245	1
JID Journal of Investigative Dermatology	6,448	1
JMIR Cancer	4,671	1
JNCCN Journal of the National Comprehensive Canc Netw	6,471	1
JNCI Journal of the National Cancer Institute	11,238	2
Journal of Cancer Research and Clinical Oncology	3,282	2
Journal of Cancer Survivorship	3,713	2
Journal of Gastrointestinal Surgery	2,813	1
Journal of Geriatric Oncology	3,359	2
Journal of Neuro-oncology	3,060	2
Journal of the European Academy of Dermatology and Ven.	4,287	1
Journal of Thoracic Disease	1,804	1
JTO Journal of Thoracic Oncology	10,336	1
Leukemia	10,023	2
Leukemia & Lymphoma	2,644	1
Lung Cancer	4,486	1
Medical Decision Making	3,012	1
Melanoma Research	3,135	1
Neuroendocrinology	5,024	1
Nutrition and Cancer	2,261	1
Oral oncology	4,636	1
Palliative Medicine	3,780	1
Patient Education and Counseling	2,785	3
PloS One	2,766	8
Prostate Cancer and Prostatic Disease	4,099	1
Psychological Medicine	5,475	1
Psycho-oncology	3,455	1
Quality of Life Research	2,392	4
Supportive Care in Cancer	2,676	7
Surgical oncology	2,558	2

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
The Breast	2,951	2
The Breast Journal	2,424	1
The Lancet	53,254	1
The Lancet Haematology	10,698	1
The Lancet Oncology	36,421	2
The Oncologist	5,306	2
Trials	2,067	1
United European Gastroenterology Journal	3,477	1
World Journal of Surgery	2,766	1

**Tabel 2** Overzicht tijdschriften zonder impactfactor

<i>Naam tijdschrift:</i>	<i>Aantal publicaties:</i>
Bladder Cancer	1
Contemporary Clinical Trials Communications	1
ERJ Open Research	1
European Urology Oncology	1
Gynecological Surgery	1
HemaSphere	1
Journal of Cancer Policy	1
Journal of Evidence-Based Medicine	1
NtvG Nederlands Tijdschrift voor Geneeskunde	6
Oncology	1
Systematic Reviews	1

Integraal Kankercentrum  
Nederland  
info@iknl.nl  
www.iknl.nl

